AU2004249497A1

AU2004249497A1 - Interferon gamma-like protein

Info

Publication number: AU2004249497A1
Application number: AU2004249497A
Authority: AU
Inventors: Ursula Boschert; Yolande Chvatchko; Richard Joseph Fagan; Alex Gutteridge; Christopher Benjamin Phelps; Christine Power
Original assignee: Ares Trading SA
Current assignee: Ares Trading SA
Priority date: 2003-06-20
Filing date: 2004-06-21
Publication date: 2004-12-29
Also published as: EP1636262A1; JP2007537696A; CA2527091A1; WO2004113379A1

Description

WO 2004/113379 PCT/GB2004/002641 I INTERFERON GAMMA-LIKE PROTEIN This invention relates to a protein, termed INSP037, herein identified as an interferon gamma-like secreted protein of the four helical bundle cytokine fold, and to the use of this protein and nucleic acid sequences from the encoding gene in the diagnosis, 5 prevention and treatment of disease. All publications, patents and patent applications cited herein are incorporated in full by reference. BACKGROUND The process of drug discovery is presently undergoing a fundamental revolution as the 10 era of functional genomics comes of age. The term "functional genomics" applies to an approach utilising bioinformatics tools to ascribe function to protein sequences of interest. Such tools are becoming increasingly necessary as the speed of generation of sequence data is rapidly outpacing the ability of research laboratories to assign functions to these protein sequences. 15 As bioinformatics tools increase in potency and in accuracy, these tools are rapidly replacing the conventional techniques of biochemical characterisation. Indeed, the advanced bioinformatics tools used in identifying the present invention are now capable of outputting results in which a high degree of confidence can be placed. Various institutions and commercial organisations are examining sequence data as 20 they become available and significant discoveries are being made on an on-going basis. However, there remains a continuing need to identify and characterise further genes and the polypeptides that they encode, as targets for research and for drug discovery. Introduction to Secreted Proteins 25 The ability of cells to make and secrete extracellular proteins is central to many biological processes. Enzymes, growth factors, extracellular matrix proteins and signalling molecules are all secreted by cells. This is through fusion of a secretory vesicle with the plasma membrane. In most cases, but not all, proteins are directed to the endoplasmic reticulum and into secretory vesicles by a signal peptide. Signal 30 peptides are cis-acting sequences that affect the transport of polypeptide chains from the cytoplasm to a membrane bound compartment such as a secretory vesicle.

WO 2004/113379 PCT/GB2004/002641 2 Polypeptides that are targeted to the secretory vesicles are either secreted into the extracellular matrix or are retained in the plasma membrane. The polypeptides that are retained in the plasma membrane will have one or more transmembrane domains. Examples of secreted proteins that play a central role in the functioning of a cell are 5 cytokines, hormones, extracellular matrix proteins (adhesion molecules), proteases, and growth and differentiation factors. Introduction to Cytokines Cytokines are a family of growth factors primarily secreted from leukocytes, and are messenger proteins that act as potent regulators capable of effecting cellular processes 10 at sub-nanomolar concentrations. Interleukins, neurotrophins, growth factors, interferons and chemokines all define cytokine families that work in conjunction with cellular receptors to regulate cell proliferation and differentiation. Their size allows cytokines to be quickly transported around the body and degraded when required. Their role in controlling a wide range of cellular functions, especially the immune 15 response and cell growth has been revealed by extensive research over the last twenty years (Boppana, S.B (1996) Indian. J. Pediatr. 63(4):447-52). Cytokines, as for other growth factors, are differentiated from classical hormones by the fact that they are produced by a number of different cell types rather than just one specific tissue or gland, and also effect a broad range of cells via interaction with specific high affinity 20 receptors located on target cells. All cytokine communication systems show both pleiotropy (one messenger producing multiple effects) and redundancy (each effect is produced by more than one messenger (Tringali, G. et al (2000) Therapie. 55(1):171-5; Tessarollo, L. (1998) Cytokine Growth Factor Rev. 9(2):125-137). An individual cytokine's effects on a cell 25 can also be dependent on its concentration, the concentration of other cytokines, the temporal sequence of cytokines, and the internal state of the cell (for example, it may be affected by the cell cycle, presence of neighbouring cells, cancerous). Although cytoldkines are typically small proteins (under 200 amino acids) they are often formed from larger precursors which are post-translationally spliced. This, in 30 addition to mRNA alternative splicing pathways, give a wide spectrum of variants of each cytokine each of which may differ substantially in biological effect. Membrane and extracellular matrix associated forms of many cytokines have also been isolated WO 2004/113379 PCT/GB2004/002641 3 (Okada-Ban, M. et al (2000) Int. J. Biochem. Cell Biol. 32(3):263-267; Atamas, S.P. (1997) Life Sci. 61(12):1105-1112). Cytokines can be grouped into families, though most are unrelated. Categorisation is usually based on secondary structure composition, as sequence similarity is often very 5 low. The families are named after the archetypal member e.g. IFN-like, IL2-like, ILl like, 11-6 like and TNF-like (Zlotnik, A. et al., (2000) Immunity. 12(2):121-127). Studies have shown cytokines are involved in many important reactions in multi cellular organisms such as immune response regulation (Nishihira, J. (1998) Int. J. Mol. Med. 2(1):17-28), inflammation (Kim, P.K. et al., (2000) Surg. Clin. North. Am. 10 80(3):885-894), wound healing (Clark, R.A. (1991) J. Cell Biochem. 46(1):1-2), embryogenesis and development, and apoptosis (Flad, H.D. et al., (1999) Pathobiology. 67(5-6):291-293). Pathogenic organisms (both viral and bacterial) such as HIV and Kaposi's sarcoma-associated virus encode anti-cytokine factors as well as cytokine analogues, which allow them to interact with cytokine receptors and control 15 the body's immune response (Sozzani, S. et al., (2000) Pharm. Acta. Helv. 74(2 3):305-312; Aoki, Y. et al., (2000) J. Hematother. Stem Cell Res. 9(2):137-145). Virally encoded cytokines, virokines, have been shown to be required for pathogenicity of viruses due to their ability to mimic and subvert the host immune system. 20 Cytokines may be useful for the treatment, prevention and/or diagnosis of a wide variety of medical conditions and diseases, including immune disorders, such as autoimmune disease, rheumatoid arthritis, osteoarthritis, psoriasis, systemic lupus erythematosus, and multiple sclerosis, inflammatory disorders, such as allergy, rhinitis, conjunctivitis, glomerulonephritis, uveitis, Crohn's disease, ulcerative colitis, 25 inflammatory bowel disease, pancreatitis, digestive system inflammation, sepsis, endotoxic shock, septic shock, cachexia, myalgia, ankylosing spondylitis, myasthenia gravis, post-viral fatigue syndrome, pulmonary disease, respiratory distress syndrome, asthma, chronic-obstructive pulmonary disease, airway inflammation, wound healing, endometriosis, dermatological disease, Behcet's disease, neoplastic disorders, such as 30 melanoma, sarcoma, renal tumour, colon tumour, haematological disease, myeloproliferative disorder, Hodgkin's disease, osteoporosis, obesity, diabetes, gout, cardiovascular disorders, reperfusion injury, atherosclerosis, ischaemic heart disease, cardiac failure, stroke, liver disease, AIDS, AIDS related complex, neurological WO 2004/113379 PCT/GB2004/002641 4 disorders, male infertility, ageing and infections, including plasmodium infection, bacterial infection and viral infection. Clinical use of cytokines has focused on their role as regulators of the immune system (Rodriguez, F.H. et al., (2000) Curr. Pharm. Des. 6(6):665-680) for instance in 5 promoting a response against thyroid cancer (Schmutzler, C. et al., (2000) 143(1):15 24). Their control of cell growth and differentiation has also made cytokines anti cancer targets (Lazar-Molnar, E. et al., (2000) Cytokine. 12(6):547-554; Gado, K. (2000) 24(4):195-209). Novel mutations in cytokines and cytokine receptors have been shown to confer disease resistance in some cases (van Deventer, S.J. et al., 10 (2000) Intensive Care Med. 26 (Suppl 1):S98:S102). The creation of synthetic cytokines (muteins) in order to modulate activity and remove potential side effects has also been an important avenue of research (Shanafelt, A.B. et al., (1998) 95(16):9454 9458). Thus, cytokine molecules have been shown to play a role in diverse physiological 15 functions, many of which can play a role in disease processes. Alteration of their activity is a means to alter the disease phenotype and as such identification of novel cytoldkine molecules is highly relevant as they may play a role in or be useful in the development of treatments for the diseases identified above, as well as other disease states. 20 Introduction to Interferons Interferons are members of the four-helical bundle family of cytokines. They are classified as Type I or Type II depending on their structure and their stability in acid medium. Type I interferons are classified into five groups on the basis of their sequence: interferon-alpha (IFN-a), interferon-beta (IFN-13), interferon-omega (IFN 25 0) and interferon-tau (IFN-T). The only Type II interferon so far identified is interferon-gamma (IFN-y) which is produced by activated T cells and NK cells. The genes for Type I interferons are clustered on human chromosome 9. In humans, it is estimated that there are at least 14 IFN-a non-allelic genes and the number of naturally-occurring IFN-ca proteins is increased further by allelic forms of IFN-a 30 genes (Jussain et al, 1996, J. Interferon Cytokine Res 16: 853-9).

WO 2004/113379 PCT/GB2004/002641 5 Interferons exert their cellular activities by binding to specific membrane receptors on the cell surface, so initiating a complex sequence of intracellular events. Type I interferons induce a wide variety of biological responses which include antiviral, immunomodulatory and anti-proliferative effects and, as a result of these effects, they 5 have proved to be effective in the treatment of diverse diseases and conditions. Interferons are potent antiviral agents and alpha-interferons, in particular, have been found to be useful in the treatment of a variety of viral infections including human papillomavirus infection, Hepatitis B and Hepatitis C infections (Jaeckel et al, 2001, 345(2): 1452-7). Type I interferons also inhibit cellular proliferation and alpha 10 interferons have been used clinically for many years in the treatment of a variety of malignancies including hairy cell leukaemia, multiple myeloma, chronic lymphocytic leukaemia, low-grade lymphoma, Kaposi's sarcoma, chronic myelogenous leukaemia, renal-cell carcinoma, and ovarian cancer. In addition, type I interferons are useful in treating autoimmune diseases, with interferon-beta having been approved for the 15 treatment of multiple sclerosis. Interferon-tau was initially identified in conceptus homogenates in ruminants although it has since been identified in humans (see WO96/35789). Although interferon-tau displays many similar activities to other Type-I interferons, it also displays some different effects. In particular, it has an anti-luteolyic effect which 20 promotes the establishment and maintenance of pregnancy (Martal et al, Reprod. Fertil Dev., 1997, 9(3): 355-80). In addition, whilst viral induction of interferon-alpha and interferon-beta is transient, lasting a few hours, viral induction of interferon-tau expression can last several days and has been found to have antiretroviral effects against HIV-1 (Dereuddre-Bosquet et al, J. Acquir. Immune Defic Syndr. Hum. 25 Retrovirol, 1996, 11(3): 241-6). Type II interferons (including interferon gamma) may be useful for the treatment, prevention and/or diagnosis of medical conditions and diseases which include immune disorders, such as autoimmune disease, rheumatoid arthritis, osteoarthritis, psoriasis, systemic lupus erythematosus, and multiple sclerosis, myastenia gravis, 30 Guillain-Barr6 syndrome, Graves disease, autoimmune alopecia, scleroderma, psoriasis (Kimball et al., Arch Dermatol 2002 Oct:138(10):1341-6) and graft-versus host disease (Miura Y., et al., Blood 2002 Oct 1:100(7):2650-8), monocyte and WO 2004/113379 PCT/GB2004/002641 6 neutrophil dysfunction, attenuated B cell function, inflammatory disorders, such as acute inflammation, septic shock, asthma, anaphylaxis, eczema, dermatitis, allergy, rhinitis, conjunctivitis, glomerulonephritis, uveitis, Sjogren's disease (Anaya et al., J Rheumatol 2002 Sep; 29(9):1874-6), Crohn's disease (Schmit A. et al., Eur Cytokine 5 Netw 2002 Jul-Sep:13(3):298-305), ulcerative colitis, inflammatory bowel disease, pancreatitis, digestive system inflammation, ulcerative colitis, sepsis, endotoxic shock, septic shock, cachexia, myalgia, ankylosing spondylitis, myasthenia gravis, post-viral fatigue syndrome, pulmonary disease, respiratory distress syndrome, asthma, chronic-obstructive pulmonary disease, airway inflammation, wound healing, 10 type I and type II diabetes, endometriosis, dermatological disease, Behcet's disease, immuno-deficiency disorders, chronic lung disease (Oei J et al., Acta Paediatr 2002:91(11):1194-9), aggressive and chronic periodontitis (Gonzales JR, et al., J clin Periodontol 2002 Sep:29(9):816-22), cancers including carcinomas, sarcomas, lymphomas, renal tumour, colon tumour, Hodgkin's disease, melanomas, such as 15 metastatic melanomas (Vaishampayan U, Clin Cancer Res 2002 Dec:8(12):3696 701), mesotheliomas, Burkitt's lymphoma, neuroblastoma, haematological disease, nasopharyngeal carcinomas, leukemias, myelomas, myeloproliferative disorder and other neoplastic diseases, osteoporosis, obesity, diabetes, gout, cardiovascular disorders, reperfusion injury, atherosclerosis, ischaemic heart disease, cardiac failure, 20 stroke, liver disease such as chronic hepatitis (Semin Liver Dis 2002:22 Suppl 1:7), AIDS (Dereuddre-Bosquet N., et al., J Acquir Immune Defic Syndr Hum Retroviol 1996 Mar 1: 11(3):241-6), AIDS related complex, neurological disorders, fibrotic diseases, male infertility, ageing and infections, including plasmodium infection, bacterial infection, fungal diseases, such as ringworm, histoplasmosis, blastomycosis, 25 aspergillosis, cryptococcosis, sporotrichosis, coccidioidocomycosis, paracoccidiomycosis and candidiasis, diseases associated with antimicrobial immunity (Bogdan, Current Opinion in Immunology 2000, 12:419-424), Peyronie's disease (Lacy et al., Int J Impot Res 2002 Oct:14(5):336-9), tuberculosis (Dieli et al., J Infect Dis 2002 Dec 15;186(12):1835-9), and viral infection (Pfeffer LM, Semin 30 Oncol 1997 Jun 24:S9-63-69). In summary, secreted proteins that are members of the four helical bundle cytokine family have been shown to play a role in diverse physiological functions, many of which can play a role in disease processes. In particular, interferons have been found to play an WO 2004/113379 PCT/GB2004/002641 7 important role in a variety of physiological processes and as a result, have proved to be useful in the treatment of a wide range of diseases. However, there remains a need for the identification of novel interferons to enable new drugs to be developed for the treatment and prevention of disease, including those diseases mentioned above. 5 THE INVENTION The invention is based on the discovery that the INSPO37 protein is an interferon gamma-like secreted protein of the four helical bundle cytokine fold. In one embodiment of the first aspect of the invention, there is provided a polypeptide, which polypeptide: 10 (i) comprises the amino acid sequence as recited in SEQ ID NO:2; (ii) is a fragment thereof that is an interferon gamma-like secreted protein of the four helical bundle cytokine fold, or having an antigenic determinant in common with the polypeptides of (i); or (iii) is a functional equivalent of (i) or (ii). 15 According to a second embodiment of this first aspect of the invention, there is provided a polypeptide which: (i) consists of the amino acid sequence as recited in SEQ ID NO:2; (ii) is a fragment thereof that is an interferon gamma-like secreted protein of the four helical bundle cytokine fold, or having an antigenic determinant in 20 common with the polypeptides of (i); or (iii) is a functional equivalent of (i) or (ii). The polypeptide having the sequence recited in SEQ ID NO:2 is referred to hereafter as "the INSP037 polypeptide". INSPO37 is also referred to herein as IPAAA44548. Preferably, the INSPO37 polypeptides according to the first aspect of the invention 25 function as an interferon gamma-like secreted protein of the four helical bundle cytokine fold. The term "interferon gamma-like secreted protein of the four helical bundle cytokine fold" will be understood by the skilled person, who will readily be able to ascertain whether a polypeptide functions as a member of this class using one of a variety of assays known in the art. The presence of a four helical bundle cytokine 30 fold may be identified by an analysis of protein sequence and secondary structure.

WO 2004/113379 PCT/GB2004/002641 8 Interferon activity is often measured as an anti-viral activity or antiproliferative activity on cancer cells. Examples of assays may be found in Schiller J.H., J Interferon Res 1986; 6(6):615-25, Gibson, U.E. et al., J Immunol Methods (1989) 20; 125(1-2):105-13 and Chang et al., J. Biol. Chem. (2002) 277(9):7118-7126. 5 In a second aspect, the invention provides a purified nucleic acid molecule which encodes a polypeptide of the first aspect of the invention. Preferably, the purified nucleic acid molecule comprises the nucleic acid sequence as recited in SEQ ID NO:1 (encoding the INSPO37 polypeptide). Preferably, the purified nucleic acid molecule consists of the nucleic acid sequence as recited in SEQ 10 ID NO:1 (encoding the INSPO37 polypeptide) or is a redundant equivalent or fragment of this sequence. In a third aspect, the invention provides a purified nucleic acid molecule which hybridizes under high stringency conditions with a nucleic acid molecule of the second aspect of the invention. 15 In a fourth aspect, the invention provides a vector, such as an expression vector, that contains a nucleic acid molecule of the second or third aspect of the invention. Examples of such vectors include pDEST14-IPAAA44548-6HIS (see Figure 10), PCRII-TOPO-IPAAA44548 (see Figure 11), pDEST14-IPAAA44548-6HIS (see Figure 12) and pEAK12D-IPAAA44548-6HIS (see Figure 13). 20 In a fifth aspect, the invention provides a host cell transformed with a vector of the fourth aspect of the invention. In a sixth aspect, the invention provides a ligand which binds specifically to, and which preferably inhibits the secreted protein activity, more preferably inhibits the interferon gamma-like activity of a polypeptide of the first aspect of the invention. 25 In a seventh aspect, the invention provides a compound that is effective to alter the expression of a natural gene which encodes a polypeptide of the first aspect of the invention or to regulate the activity of a polypeptide of the first aspect of the invention. A compound of the seventh aspect of the invention may either increase (agonise) or 30 decrease (antagonise) the level of expression of the gene or the activity of the polypeptide.

WO 2004/113379 PCT/GB2004/002641 9 Importantly, the identification of the function of the INSPO37 polypeptide allows for the design of screening methods capable of identifying compounds that are effective in the treatment and/or diagnosis of disease. Ligands and compounds according to the sixth and seventh aspects of the invention may be identified using such methods. 5 These methods are included as aspects of the present invention. Using these methods, it will now be possible to identify inhibitors or antagonists of INSPO37, such as, for example, monoclonal antibodies, which may be of use in modulating INSPO37 activity in vivo in clinical applications. Such compounds are likely to be useful in counteracting the IFNy-like activity of the INSPO37 polypeptides. 10 In an eighth aspect, the invention provides a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a host cell of the fifth aspect of the invention, or a ligand of the sixth aspect of the invention, or a compound of the seventh aspect of the invention, for use in therapy or diagnosis of diseases in which 15 interferons are implicated, particularly IFN-y-like polypeptides. Such diseases include, but are not limited to, immune disorders, such as autoimmune disease, rheumatoid arthritis, osteoarthritis, psoriasis, systemic lupus erythematosus, and multiple sclerosis, myastenia gravis, Guillain-Barr6 syndrome, Graves disease, autoimmune alopecia, scleroderma, psoriasis (Kimball et al., Arch Dermatol 2002 20 Oct:138(10):1341-6) and graft-versus-host disease (Miura Y., et al., Blood 2002 Oct 1:100(7):2650-8), monocyte and neutrophil dysfunction, attenuated B cell function, inflammatory disorders, such as acute inflammation, septic shock, asthma, anaphylaxis, eczema, dermatitis, allergy, rhinitis, conjunctivitis, glomerulonephritis, uveitis, Sjogren's disease (Anaya et al., J Rheumatol 2002 Sep; 29(9):1874-6), 25 Crohn's disease (Schmit A. et al., Eur Cytokine Netw 2002 Jul-Sep:13(3):298-305), ulcerative colitis, inflammatory bowel disease, pancreatitis, digestive system inflammation, ulcerative colitis, sepsis, endotoxic shock, septic shock, cachexia, myalgia, ankylosing spondylitis, myasthenia gravis, post-viral fatigue syndrome, pulmonary disease, respiratory distress syndrome, asthma, chronic-obstructive 30 pulmonary disease, airway inflammation, wound healing, type I and type II diabetes, endometriosis, dermatological disease, Behcet's disease, immuno-deficiency disorders, chronic lung disease (Oei J et al., Acta Paediatr 2002:91(11):1194-9), aggressive and chronic periodontitis (Gonzales JR, et al., J dclin Periodontol 2002 WO 2004/113379 PCT/GB2004/002641 10 Sep:29(9):816-22), cancers including carcinomas, sarcomas, lymphomas, renal tumour, colon tumour, Hodgkin's disease, melanomas, such as metastatic melanomas (Vaishampayan U, Clin Cancer Res 2002 Dec:8(12):3696-701), mesotheliomas, Burkitt's lymphoma, neuroblastoma, haematological disease, nasopharyngeal 5 carcinomas, leukemias, myelomas, myeloproliferative disorder and other neoplastic diseases, osteoporosis, obesity, diabetes, gout, cardiovascular disorders, reperfusion injury, atherosclerosis, ischaemic heart disease, cardiac failure, stroke, liver disease such as chronic hepatitis (Semin Liver Dis 2002:22 Suppl 1:7), AIDS (Dereuddre Bosquet N., et al., J Acquir Immune Defic Syndr Hum Retroviol 1996 Mar 1: 10 11(3):241-6), AIDS related complex, neurological disorders, fibrotic diseases, male infertility, ageing and infections, including plasmodium infection, bacterial infection, fungal diseases, such as ringworm, histoplasmosis, blastomycosis, aspergillosis, cryptococcosis, sporotrichosis, coccidioidocomycosis, paracoccidiomycosis and candidiasis, diseases associated with antimicrobial immunity (Bogdan, Current 15 Opinion in Immunology 2000, 12:419-424), Peyronie's disease (Lacy et al., Int J Impot Res 2002 Oct:14(5):336-9), tuberculosis (Dieli et al., J Infect Dis 2002 Dec 15;186(12):1835-9), and viral infection (Pfeffer LM, Semin Oncol 1997 Jun 24:S9 63-69). These moieties of the first, second, third, fourth, fifth, sixth or seventh aspect of the 20 invention may also be used in the manufacture of a medicament for the treatment of such diseases. In a ninth aspect, the invention provides a method of diagnosing a disease in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide of the first aspect of the invention or the activity of a polypeptide of the first aspect of 25 the invention in tissue from said patient and comparing said level of expression or activity to a control level, wherein a level that is different to said control level is indicative of disease. Such a method will preferably be carried out in vitro. Similar methods may be used for monitoring the therapeutic treatment of disease in a patient, wherein altering the level of expression or activity of a polypeptide or nucleic acid 30 molecule over the period of time towards a control level is indicative of regression of disease. A preferred method for detecting polypeptides of the first aspect of the invention comprises the steps of: (a) contacting a ligand, such as an antibody, of the sixth aspect WO 2004/113379 PCT/GB2004/002641 11 of the invention with a biological sample under conditions suitable for the formation of a ligand-polypeptide complex; and (b) detecting said complex. A number of different such methods according to the ninth aspect of the invention exist, as the skilled reader will be aware, such as methods of nucleic acid 5 hybridization with short probes, point mutation analysis, polymerase chain reaction (PCR) amplification and methods using antibodies to detect aberrant protein levels. Similar methods may be used on a short or long term basis to allow therapeutic treatment of a disease to be monitored in a patient. The invention also provides kits that are useful in these methods for diagnosing disease. 10 Preferably, the disease diagnosed by a method of the ninth aspect of the invention is a disease in which interferons are implicated, as described above. In a tenth aspect, the invention provides for the use of the polypeptide of the first aspect of the invention as an interferon gamma-like secreted protein of the four helical bundle cytokine fold. One suitable use of INSPO37 is use as an adjuvant in bacterial, 15 fungal or viral infections, in conjunction with well-established treatments. Other potential uses include use of INSPO37 to activate macrophages, and to increase expression of MHC molecules and antigen processing components. Experimental results included herein confirm the predicted IFNy-like activity of INSPO37. This discovery opens a series of interesting therapeutic applications for the protein per se, 20 in that the polypeptides of the invention can be tested for suitability for use in known applications of IFNy, such as in anti-cancer applications (see, for example, Vaishampayan U, Clin Cancer Res 2002 Dec:8(12):3696-701). It will also now be possible to identify inhibitors or antagonists of INSPO37, such as, for example, monoclonal antibodies, which may be of use in further studies of INSPO37 activity in 25 vivo or in clinical applications. In an eleventh aspect, the invention provides a pharmaceutical composition comprising a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a host cell of the fifth aspect of the invention, or a ligand of the 30 sixth aspect of the invention, or a compound of the seventh aspect of the invention, in conjunction with a pharmaceutically-acceptable carrier.

WO 2004/113379 PCT/GB2004/002641 12 In a twelfth aspect, the present invention provides a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a host cell of the fifth aspect of the invention, or a ligand of the sixth aspect of the invention, or a compound 5 of the seventh aspect of the invention, for use in the manufacture of a medicament for the diagnosis or treatment of a disease in which interferons are implicated. Such diseases include those described above in connection with the eighth aspect of the invention. In a thirteenth aspect, the invention provides a method of treating a disease in a 10 patient comprising administering to the patient a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a host cell of the fifth aspect of the invention, or a ligand of the sixth aspect of the invention, or a compound of the seventh aspect of the invention. 15 For diseases in which the expression of a natural gene encoding a polypeptide of the first aspect of the invention, or in which the activity of a polypeptide of the first aspect of the invention, is lower in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, vector, host cell, ligand or compound administered to the patient should be an agonist. 20 Conversely, for diseases in which the expression of the natural gene or activity of the polypeptide is higher in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, vector, host cell, ligand or compound administered to the patient should be an antagonist. Examples of such antagonists include antisense nucleic acid molecules, ribozymes 25 and ligands, such as antibodies. Preferably, the disease is a disease in which interferons are implicated, as described above. In a fourteenth aspect, the invention provides transgenic or knockout non-human animals that have been transformed to express higher, lower or absent levels of a 30 polypeptide of the first aspect of the invention. Such transgenic animals are very useful models for the study of disease and may also be used in screening regimes for the identification of compounds that are effective in the treatment or diagnosis of such WO 2004/113379 PCT/GB2004/002641 13 a disease. Preferably, the disease is a disease in which interferons are implicated, as described above. A summary of standard techniques and procedures which may be employed in order 5 to utilise the invention is given below. It will be understood that this invention is not limited to the particular methodology, protocols, cell lines, vectors and reagents described. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and it is not intended that this terminology should limit the scope of the present invention. The extent of the 10 invention is limited only by the terms of the appended claims. Standard abbreviations for nucleotides and amino acids are used in this specification. The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA technology and immunology, which are within the skill of those working in the art. 15 Such techniques are explained fully in the literature. Examples of particularly suitable texts for consultation include the following: Sambrook Molecular Cloning; A Laboratory Manual, Second Edition (1989); DNA Cloning, Volumes I and II (D.N Glover ed. 1985); Oligonucleotide Synthesis (M.J. Gait ed. 1984); Nucleic Acid Hybridization (B.D. Hames & S.J. Higgins eds. 1984); Transcription and Translation 20 (B.D. Hames & S.J. Higgins eds. 1984); Animal Cell Culture (R.I. Freshney ed. 1986); Immobilized Cells and Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide to Molecular Cloning (1984); the Methods in Enzymology series (Academic Press, Inc.), especially volumes 154 & 155; Gene Transfer Vectors for Mammalian Cells (J.H. Miller and M.P. Calos eds. 1987, Cold Spring Harbor Laboratory); 25 Immunochemical Methods in Cell and Molecular Biology (Mayer and Walker, eds. 1987, Academic Press, London); Scopes, (1987) Protein Purification: Principles and Practice, Second Edition (Springer Verlag, N.Y.); and Handbook of Experimental Immunology, Volumes I-IV (D.M. Weir and C. C. Blackwell eds. 1986). As used herein, the term "polypeptide" includes any peptide or protein comprising 30 two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e. peptide isosteres. This term refers both to short chains (peptides and oligopeptides) and to longer chains (proteins).

WO 2004/113379 PCT/GB2004/002641 14 The polypeptide of the present invention may be in the form of a mature protein or may be a pre-, pro- or prepro- protein that can be activated by cleavage of the pre-, pro- or prepro- portion to produce an active mature polypeptide. In such polypeptides, the pre-, pro- or prepro- sequence may be a leader or secretory sequence or may be a 5 sequence that is employed for purification of the mature polypeptide sequence. The polypeptide of the first aspect of the invention may form part of a fusion protein. For example, it is often advantageous to include one or more additional amino acid sequences which may contain secretory or leader sequences, pro-sequences, sequences which aid in purification, or sequences that confer higher protein stability, 10 for example during recombinant production. Alternatively or additionally, the mature polypeptide may be fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol). Polypeptides may contain amino acids other than the 20 gene-encoded amino acids, modified either by natural processes, such as by post-translational processing or by 15 chemical modification techniques which are well known in the art. Among the known modifications which may commonly be present in polypeptides of the present invention are glycosylation, lipid attachment, sulphation, gamma-carboxylation, for instance of glutamic acid residues, hydroxylation and ADP-ribosylation. Other potential modifications include acetylation, acylation, amidation, covalent attachment 20 of flavin, covalent attachment of a haeme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulphide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, GPI anchor formation, iodination, 25 methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. In fact, blockage of the 30 amino or carboxyl terminus in a polypeptide, or both, by a covalent modification is common in naturally-occurring and synthetic polypeptides and such modifications may be present in polypeptides of the present invention.

WO 2004/113379 PCT/GB2004/002641 15 The modifications that occur in a polypeptide often will be a function of how the polypeptide is made. For polypeptides that are made recombinantly, the nature and extent of the modifications in large part will be determined by the post-translational modification capacity of the particular host cell and the modification signals that are 5 present in the amino acid sequence of the polypeptide in question. For instance, glycosylation patterns vary between different types of host cell. The polypeptides of the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally-occurring polypeptides (for example purified from cell culture), recombinantly-produced polypeptides (including fusion 10 proteins), synthetically-produced polypeptides or polypeptides that are produced by a combination of these methods. The functionally-equivalent polypeptides of the first aspect of the invention may be polypeptides that are homologous to the INSPO37 polypeptides. Two polypeptides are said to be "homologous", as the term is used herein, if the sequence of one of the 15 polypeptides has a high enough degree of identity or similarity to the sequence of the other polypeptide. "Identity" indicates that at any particular position in the aligned sequences, the amino acid residue is identical between the sequences. "Similarity" indicates that, at any particular position in the aligned sequences, the amino acid residue is of a similar type between the sequences. Degrees of identity and similarity 20 can be readily calculated (Computational Molecular Biology, Lesk, A.M., ed., Oxford University Press, New York, 1988; Biocomputing. Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part 1, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and 25 Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). Preferably, percentage identity, as referred to herein, is as determined using BLAST version 2.1.3 using the default parameters specified by the NCBI (the National Center for Biotechnology Information; http://www.ncbi.nlm.nih.gov/) [Blosum 62 matrix; gap open penalty=1 1 and gap 30 extension penalty= 1]. Homologous polypeptides therefore include natural biological variants (for example, allelic variants or geographical variations within the species from which the polypeptides are derived) and mutants (such as mutants containing amino acid WO 2004/113379 PCT/GB2004/002641 16 substitutions, insertions or deletions) of the INSPO37 polypeptides. Such mutants may include polypeptides in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded 5 by the genetic code. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; among the basic residues Lys and Arg; or among the aromatic residues Phe and Tyr. Particularly preferred are variants in which several, i.e. between 5 and 10, 1 and 5, 1 and 3, 1 and 2 or just 1 amino acids are substituted, deleted or added in any 10 combination. Especially preferred are silent substitutions, additions and deletions, which do not alter the properties and activities of the protein. Also especially preferred in this regard are conservative substitutions. Such mutants also include polypeptides in which one or more of the amino acid residues includes a substituent group. 15 Typically, greater than 80% identity between two polypeptides is considered to be an indication of functional equivalence. Preferably, functionally equivalent polypeptides of the first aspect of the invention have a degree of sequence identity with the INSPO37 polypeptide, or with active fragments thereof, of greater than 80%. More preferred polypeptides have degrees of identity of greater than 90%, 95%, 98% or 20 99%, respectively. The functionally-equivalent polypeptides of the first aspect of the invention may also be polypeptides which have been identified using one or more technlmiques of structural alignment. For example, the Inphannatica Genome Threader technology that forms one aspect of the search tools used to generate the Biopendium search database may 25 be used (see PCT application published as WO 01/69507) to identify polypeptides of presently-unknown function which, while having low sequence identity as compared to the INSPO37 polypeptides, are predicted to be interferon gamma-like secreted proteins of the four helical bundle cytokine fold by virtue of sharing significant structural homology with the INSPO37 polypeptide sequences. By "significant 30 structural homology" is meant that the Inpharmatica Genome Threader predicts two proteins to share structural homology with a certainty of 10% and above. The polypeptides of the first aspect of the invention also include fragments of the WO 2004/113379 PCT/GB2004/002641 17 INSP037 polypeptides and fragments of the functional equivalents of these polypeptides, provided that those fragments retain interferon gamma-like activity, or have an antigenic determinant in common with these polypeptides. As used herein, the term "fragment" refers to a polypeptide having an amino acid 5 sequence that is the same as part, but not all, of the amino acid sequence of INSPO37 polypeptides or one of its functional equivalents. The fragments should comprise at least n consecutive amino acids from the sequence and, depending on the particular sequence, n preferably is 7 or more (for example, 8, 10, 12, 14, 16, 18, 20 or more). Small fragments may form an antigenic determinant. 10 Such fragments may be "free-standing", i.e. not part of or fused to other amino acids or polypeptides, or they may be comprised within a larger polypeptide of which they form a part or region. When comprised within a larger polypeptide, the fragment of the invention most preferably forms a single continuous region. For instance, certain preferred embodiments relate to a fragment having a pre- and/or pro- polypeptide 15 region fused to the amino terminus of the fragment and/or an additional region fused to the carboxyl terminus of the fragment. However, several fragments may be comprised within a single larger polypeptide. The polypeptides of the present invention or their immunogenic fragments (comprising at least one antigenic determinant) can be used to generate ligands, such 20 as polyclonal or monoclonal antibodies, that are immunospecific for the polypeptides. Such antibodies may be employed to isolate or to identify clones expressing the polypeptides of the invention or to purify the polypeptides by affinity chromatography. The antibodies may also be employed as diagnostic or therapeutic aids, amongst other applications, as will be apparent to the skilled reader. 25 The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art. As used herein, the term "antibody" refers to intact molecules as well as to fragments thereof, such as Fab, F(ab')2 and Fv, which are capable of binding to the antigenic determinant in question. Such antibodies thus bind 30 to the polypeptides of the first aspect of the invention. By "substantially greater affinity" we mean that there is a measurable increase in the affinity for a polypeptide of the invention as compared with the affinity for known WO 2004/113379 PCT/GB2004/002641 18 cell-surface receptors. Preferably, the affinity is at least 1.5-fold, 2-fold, 5-fold 10-fold, 100-fold, 10 3 -fold, 10 4 -fold, 10 5 -fold, 10 6 -fold or greater for a polypeptide of the invention than for known IFNy-like polypeptides. 5 If polyclonal antibodies are desired, a selected mammal, such as a mouse, rabbit, goat or horse, may be immunised with a polypeptide of the first aspect of the invention. The polypeptide used to immunise the animal can be derived by recombinant DNA technology or can be synthesized chemically. If desired, the polypeptide can be conjugated to a carrier protein. Commonly used carriers to which the polypeptides 10 may be chemically coupled include bovine serum albumin, thyroglobulin and keyhole limpet haemocyanin. The coupled polypeptide is then used to immunise the animal. Serum from the immunised animal is collected and treated according to known procedures, for example by immunoaffmity chromatography. Monoclonal antibodies to the polypeptides of the first aspect of the invention can also 15 be readily produced by one skilled in the art. The general methodology for making monoclonal antibodies using hybridoma technology is well known (see, for example, Kohler, G. and Milstein, C., Nature 256: 495-497 (1975); Kozbor et al., Immunology Today 4: 72 (1983); Cole et al., 77-96 in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. (1985). 20 Panels of monoclonal antibodies produced against the polypeptides of the first aspect of the invention can be screened for various properties, i.e., for isotype, epitope, affinity, etc. Monoclonal antibodies are particularly useful in purification of the individual polypeptides against which they are directed. Alternatively, genes encoding the monoclonal antibodies of interest may be isolated from hybridomas, for instance 25 by PCR techniques known in the art, and cloned and expressed in appropriate vectors. Chimeric antibodies, in which non-human variable regions are joined or fused to human constant regions (see, for example, Liu et al., Proc. Natl. Acad. Sci. USA, 84, 3439 (1987)), may also be of use. The antibody may be modified to make it less immunogenic in an individual, for 30 example by humanisation (see Jones et al., Nature, 321, 522 (1986); Verhoeyen et al., Science, 239, 1534 (1988); Kabat et al., J. Immunol., 147, 1709 (1991); Queen et al., Proc. Natl Acad. Sci. USA, 86, 10029 (1989); Gormnan et al., Proc. Natl Acad. Sci.

WO 2004/113379 PCT/GB2004/002641 19 USA, 88, 34181 (1991); and Hodgson et al., Bio/Technology, 9, 421 (1991)). The term "humanised antibody", as used herein, refers to antibody molecules in which the CDR amino acids and selected other amino acids in the variable domains of the heavy and/or light chains of a non-human donor antibody have been substituted in place of 5 the equivalent amino acids in a human antibody. The humanised antibody thus closely resembles a human antibody but has the binding ability of the donor antibody. In a further alternative, the antibody may be a "bispecific" antibody, that is an antibody having two different antigen-binding domains, each domain being directed against a different epitope. 10 Phage display technology may be utilised to select genes which encode antibodies with binding activities towards the polypeptides of the invention either from repertoires of PCR amplified V-genes of lymphocytes from humans screened for possessing the relevant antibodies, or from naive libraries (McCafferty, J. et al., (1990), Nature 348, 552-554; Marks, J. et al., (1992) Biotechnology 10, 779-783). 15 The affinity of these antibodies can also be improved by chain shuffling (Clackson, T. et al., (1991) Nature 352, 624-628). Antibodies generated by the above techniques, whether polyclonal or monoclonal, have additional utility in that they may be employed as reagents in immunoassays, radioimmunoassays (RIA) or enzyme-linked immunosorbent assays (ELISA). In these 20 applications, the antibodies can be labelled with an analytically-detectable reagent such as a radioisotope, a fluorescent molecule or an enzyme. Preferred nucleic acid molecules of the second and third aspects of the invention are those which encode a polypeptide sequences as recited in SEQ ID NO:2 and functionally equivalent polypeptides. These nucleic acid molecules may be used in the 25 methods and applications described herein. The nucleic acid molecules of the invention preferably comprise at least n consecutive nucleotides from the sequences disclosed herein where, depending on the particular sequence, n is 10 or more (for example, 12, 14, 15, 18, 20, 25, 30, 35, 40 or more). The nucleic acid molecules of the invention also include sequences that are 30 complementary to nucleic acid molecules described above (for example, for antisense or probing purposes). Nucleic acid molecules of the present invention may be in the form of RNA, such as WO 2004/113379 PCT/GB2004/002641 20 mRNA, or in the form of DNA, including, for instance eDNA, synthetic DNA or genomic DNA. Such nucleic acid molecules may be obtained by cloning, by chemical synthetic techniques or by a combination thereof. The nucleic acid molecules can be prepared, for example, by chemical synthesis using techniques such as solid phase 5 phosphoramidite chemical synthesis, from genomic or cDNA libraries or by separation from an organism. RNA molecules may generally be generated by the in vitro or in vivo transcription of DNA sequences. The nucleic acid molecules may be double-stranded or single-stranded. Single stranded DNA may be the coding strand, also known as the sense strand, or it may be 10 the non-coding strand, also referred to as the anti-sense strand. The term "nucleic acid molecule" also includes analogues of DNA and RNA, such as those containing modified backbones, and peptide nucleic acids (PNA). The term "PNA", as used herein, refers to an antisense molecule or an anti-gene agent which comprises an oligonucleotide of at least five nucleotides in length linked to a peptide 15 backbone of amino acid residues, which preferably ends in lysine. The terminal lysine confers solubility to the composition. PNAs may be pegylated to extend their lifespan in a cell, where they preferentially bind complementary single stranded DNA and RNA and stop transcript elongation (Nielsen, P.E. et al. (1993) Anticancer Drug Des. 8:53-63). 20 A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:2 may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO: 1. These molecules also may have a different sequence which, as a result of the degeneracy of the genetic code, encodes a polypeptide of SEQ ID NO:2. Such nucleic acid molecules may include, but are not limited to, the coding sequence for the mature 25 polypeptide by itself; the coding sequence for the mature polypeptide and additional coding sequences, such as those encoding a leader or secretory sequence, such as a pro-, pre- or prepro- polypeptide sequence; the coding sequence of the mature polypeptide, with or without the aforementioned additional coding sequences, together with further additional, non-coding sequences, including non-coding 5' and 3' 30 sequences, such as the transcribed, non-translated sequences that play a role in transcription (including termination signals), ribosome binding and mRNA stability. The nucleic acid molecules may also include additional sequences which encode additional amino acids, such as those which provide additional functionalities.

WO 2004/113379 PCT/GB2004/002641 21 The nucleic acid molecules of the second and third aspects of the invention may also encode the fragments or the functional equivalents of the polypeptides and fragments of the first aspect of the invention. Such a nucleic acid molecule may be a naturally occurring variant such as a naturally-occurring allelic variant, or the molecule may be 5 a variant that is not known to occur naturally. Such non-naturally occurring variants of the nucleic acid molecule may be made by mutagenesis techniques, including those applied to nucleic acid molecules, cells or organisms. Among variants in this regard are variants that differ from the aforementioned nucleic acid molecules by nucleotide substitutions, deletions or insertions. The substitutions, 10 deletions or insertions may involve one or more nucleotides. The variants may be altered in coding or non-coding regions or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or insertions. The nucleic acid molecules of the invention can also be engineered, using methods 15 generally known in the art, for a variety of reasons, including modifying the cloning, processing, and/or expression of the gene product (the polypeptide). DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides are included as techniques which may be used to engineer the nucleotide sequences. Site-directed mutagenesis may be used to insert new restriction 20 sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce mutations and so forth. Nucleic acid molecules which encode a polypeptide of the first aspect of the invention may be ligated to a heterologous sequence so that the combined nucleic acid molecule encodes a fusion protein. Such combined nucleic acid molecules are included within 25 the second or third aspects of the invention. For example, to screen peptide libraries for inhibitors of the activity of the polypeptide, it may be useful to express, using such a combined nucleic acid molecule, a fusion protein that can be recognised by a commercially-available antibody. A fusion protein may also be engineered to contain a cleavage site located between the sequence of the polypeptide of the invention and 30 the sequence of a heterologous protein so that the polypeptide may be cleaved and purified away from the heterologous protein. The nucleic acid molecules of the invention also include antisense molecules that are WO 2004/113379 PCT/GB2004/002641 22 partially complementary to nucleic acid molecules encoding polypeptides of the present invention and that therefore hybridize to the encoding nucleic acid molecules (hybridization). Such antisense molecules, such as oligonucleotides, can be designed to recognise, specifically bind to and prevent transcription of a target nucleic acid 5 encoding a polypeptide of the invention, as will be known by those of ordinary skill in the art (see, for example, Cohen, J.S., Trends in Pharm. Sci., 10, 435 (1989), Okano, J. Neurochem. 56, 560 (1991); O'Connor, J. Neurochem 56, 560 (1991); Lee et al., Nucleic Acids Res 6, 3073 (1979); Cooney et al., Science 241, 456 (1988); Dervan et al., Science 251, 1360 (1991). 10 The term "hybridization" as used here refers to the association of two nucleic acid molecules with one another by hydrogen bonding. Typically, one molecule will be fixed to a solid support and the other will be free in solution. Then, the two molecules may be placed in contact with one another under conditions that favour hydrogen bonding. Factors that affect this bonding include: the type and volume of solvent; 15 reaction temperature; time of hybridization; agitation; agents to block the non-specific attachment of the liquid phase molecule to the solid support (Denhardt's reagent or BLOTTO); the concentration of the molecules; use of compounds to increase the rate of association of molecules (dextran sulphate or polyethylene glycol); and the stringency of the washing conditions following hybridization (see Sambrook et al. 20 [supra]). The inhibition of hybridization of a completely complementary molecule to a target molecule may be examined using a hybridization assay, as known in the art (see, for example, Sambrook et al [supra]). A substantially homologous molecule will then compete for and inhibit the binding of a completely homologous molecule to the 25 target molecule under various conditions of stringency, as taught in Wahl, G.M. and S.L. Berger (1987; Methods Enzymol. 152:399-407) and Kimmel, A.R. (1987; Methods Enzymol. 152:507-511). "Stringency" refers to conditions in a hybridization reaction that favour the association of very similar molecules over association of molecules that differ. High 30 stringency hybridisation conditions are defined as overnight incubation at 42'C in a solution comprising 50% formamide, 5XSSC (150mM NaC1, 15mM trisodium citrate), 50mM sodium phosphate (pH7.6), 5x Denhardts solution, 10% dextran sulphate, and 20 microgram/ml denatured, sheared salmon sperm DNA, followed by WO 2004/113379 PCT/GB2004/002641 23 washing the filters in 0.1X SSC at approximately 65 0 C. Low stringency conditions involve the hybridisation reaction being carried out at 35 0 C (see Sambrook et al. [supra]). Preferably, the conditions used for hybridization are those of high stringency. 5 Preferred embodiments of this aspect of the invention are nucleic acid molecules that are at least 70% identical over their entire length to a nucleic acid molecule encoding the INSPO37 polypeptide (SEQ ID NO:2) and nucleic acid molecules that are substantially complementary to such nucleic acid molecules. Preferably, a nucleic acid molecule according to this aspect of the invention comprises a region that is at 10 least 80% identical over its entire length to the nucleic acid molecules having the sequence produced by SEQ ID NO:1 or a nucleic acid molecule that is complementary thereto. In this regard, nucleic acid molecules at least 90%, preferably at least 95%, more preferably at least 98% or 99% identical over their entire length to the same are particularly preferred. Preferred embodiments in this respect are nucleic 15 acid molecules that encode polypeptides which retain substantially the same biological function or activity as the INSPO37 polypeptides. The invention also provides a process for detecting a nucleic acid molecule of the invention, comprising the steps of: (a) contacting a nucleic probe according to the invention with a biological sample under hybridizing conditions to form duplexes; 20 and (b) detecting any such duplexes that are formed. As discussed additionally below in connection with assays that may be utilised according to the invention, a nucleic acid molecule as described above may be used as a hybridization probe for RNA, eDNA or genomic DNA, in order to isolate full length cDNAs and genomic clones encoding the INSPO37 polypeptides and to isolate 25 eDNA and genomic clones of homologous or orthologous genes that have a high sequence similarity to the gene encoding this polypeptide. In this regard, the following techniques, among others known in the art, may be utilised and are discussed below for purposes of illustration. Methods for DNA sequencing and analysis are well known and are generally available in the art and 30 may, indeed, be used to practice many of the embodiments of the invention discussed herein. Such methods may employ such enzymes as the Klenow fragment of DNA polymerase I, Sequenase (US Biochemical Corp, Cleveland, OH), Taq polymerase WO 2004/113379 PCT/GB2004/002641 24 (Perkin Elmer), thermostable T7 polymerase (Amersham, Chicago, IL), or combinations of polymerases and proof-reading exonucleases such as those found in the ELONGASE Amplification System marketed by Gibco/BRL (Gaithersburg, MD). Preferably, the sequencing process may be automated using machines such as the 5 Hamilton Micro Lab 2200 (Hamilton, Reno, NV), the Peltier Thermal Cycler (PTC200; MJ Research, Watertown, MA) and the ABI Catalyst and 373 and 377 DNA Sequencers (Perkin Elmer). One method for isolating a nucleic acid molecule encoding a polypeptide with an equivalent function to that of the INSP037 polypeptides is to probe a genomic or 10 cDNA library with a natural or artificially-designed probe using standard procedures that are recognised in the art (see, for example, "Current Protocols in Molecular Biology", Ausubel et al. (eds). Greene Publishing Association and John Wiley Interscience, New York, 1989,1992). Probes comprising at least 15, preferably at least 30, and more preferably at least 50, contiguous bases that correspond to, or are 15 complementary to, nucleic acid sequences from the appropriate encoding gene (SEQ ID NO:l) are particularly useful probes. Such probes may be labelled with an analytically-detectable reagent to facilitate their identification. Useful reagents include, but are not limited to, radioisotopes, fluorescent dyes and enzymes that are capable of catalysing the formation of a detectable product. Using these probes, the 20 ordinarily skilled artisan will be capable of isolating complementary copies of genomic DNA, cDNA or RNA polynucleotides encoding proteins of interest from human, mammalian or other animal sources and screening such sources for related sequences, for example, for additional members of the family, type and/or subtype. In many cases, isolated cDNA sequences will be incomplete, in that the region 25 encoding the polypeptide will be cut short, normally at the 5' end. Several methods are available to obtain full length cDNAs, or to extend short cDNAs. Such sequences may be extended utilising a partial nucleotide sequence and employing various methods known in the art to detect upstream sequences such as promoters and regulatory elements. For example, one method which may be employed is based on the method 30 of Rapid Amplification of cDNA Ends (RACE; see, for example, Frohman et al., PNAS USA 85, 8998-9002, 1988). Recent modifications of this technique, exemplified by the MarathonTM technology (Clontech Laboratories Inc.), for example, have significantly simplified the search for longer cDNAs. A slightly WO 2004/113379 PCT/GB2004/002641 25 different technique, termed "restriction-site" PCR, uses universal primers to retrieve unknown nucleic acid sequence adjacent a known locus (Sarkar, G. (1993) PCR Methods Applic. 2:318-322). Inverse PCR may also be used to amplify or to extend sequences using divergent primers based on a known region (Triglia, T. et al. (1988) 5 Nucleic Acids Res. 16:8186). Another method which may be used is capture PCR which involves PCR amplification of DNA fragments adjacent a known sequence in human and yeast artificial chromosome DNA (Lagerstrom, M. et al. (1991) PCR Methods Applic., 1, 111-119). Another method which may be used to retrieve unknown sequences is that of Parker, J.D. et al. (1991); Nucleic Acids Res. 19:3055 10 3060). Additionally, one may use PCR, nested primers, and PromoterFinderTM libraries to walk genomic DNA (Clontech, Palo Alto, CA). This process avoids the need to screen libraries and is useful in finding intron/exon junctions. When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Also, random-primed libraries are preferable, 15 in that they will contain more sequences that contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length eDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions. In one embodiment of the invention, the nucleic acid molecules of the present 20 invention may be used for chromosome localisation. In this technique, a nucleic acid molecule is specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important step in the confirmatory correlation of those sequences with the gene-associated disease. Once a sequence has been 25 mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins University Welch Medical Library). The relationships between genes and diseases that have been mapped to the same chromosomal region are then 30 identified through linkage analysis (coinheritance of physically adjacent genes). This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localised by genetic linkage to a particular genomic region, any WO 2004/113379 PCT/GB2004/002641 26 sequences mapping to that area may represent associated or regulatory genes for further investigation. The nucleic acid molecule may also be used to detect differences in the chromosomal location due to translocation, inversion, etc. among normal, carrier, or affected individuals. 5 The nucleic acid molecules of the present invention are also valuable for tissue localisation. Such techniques allow the determination of expression patterns of the polypeptide in tissues by detection of the mRNAs that encode them. These techniques include in situ hybridization techniques and nucleotide amplification techniques, such as PCR. Results from these studies provide an indication of the normal functions of 10 the polypeptide in the organism. In addition, comparative studies of the normal expression pattern of mRNAs with that of mRNAs encoded by a mutant gene provide valuable insights into the role of mutant polypeptides in disease. Such inappropriate expression may be of a temporal, spatial or quantitative nature. Gene silencing approaches may also be undertaken to down-regulate endogenous 15 expression of a gene encoding a polypeptide of the invention. RNA interference (RNAi) (Elbashir, SM et al., Nature 2001, 411, 494-498) is one method of sequence specific post-transcriptional gene silencing that may be employed. Short dsRNA oligonucleotides are synthesised in vitro and introduced into a cell. The sequence specific binding of these dsRNA oligonucleotides triggers the degradation of target 20 mRNA, reducing or ablating target protein expression. Efficacy of the gene silencing approaches assessed above may be assessed through the measurement of polypeptide expression (for example, by Western blotting), and at the RNA level using TaqMan-based methodologies. The vectors of the present invention comprise nucleic acid molecules of the invention 25 and may be cloning or expression vectors. The host cells of the invention, which may be transformed, transfected or transduced with the vectors of the invention may be prokaryotic or eukaryotic. The polypeptides of the invention may be prepared in recombinant form by expression of their encoding nucleic acid molecules in vectors contained within a host 30 cell. Such expression methods are well known to those of skill in the art and many are described in detail by Sambrook et al (supra) and Fernandez & Hoeffler (1998, eds. "Gene expression systems. Using nature for the art of expression". Academic Press, WO 2004/113379 PCT/GB2004/002641 27 San Diego, London, Boston, New York, Sydney, Tokyo, Toronto). Generally, any system or vector that is suitable to maintain, propagate or express nucleic acid molecules to produce a polypeptide in the required host may be used. The appropriate nucleotide sequence may be inserted into an expression system by any of 5 a variety of well-known and routine techniques, such as, for example, those described in Sambrook et al., (supra). Generally, the encoding gene can be placed under the control of a control element such as a promoter, ribosome binding site (for bacterial expression) and, optionally, an operator, so that the DNA sequence encoding the desired polypeptide is transcribed into RNA in the transformed host cell. 10 Examples of suitable expression systems include, for example, chromosomal, episomal and virus-derived systems, including, for example, vectors derived from: bacterial plasmids, bacteriophage, transposons, yeast episomes, insertion elements, yeast chromosomal elements, viruses such as baculoviruses, papova viruses such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and 15 retroviruses, or combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, including cosmids and phagemids. Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained and expressed in a plasmid. Particularly suitable expression systems include microorganisms such as bacteria 20 transformed with recombinant bacteriophage, plasmid or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (for example, baculovirus); plant cell systems transformed with virus expression vectors (for example, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (for 25 example, Ti or pBR322 plasmids); or animal cell systems. Cell-free translation systems can also be employed to produce the polypeptides of the invention. Introduction of nucleic acid molecules encoding a polypeptide of the present invention into host cells can be effected by methods described in many standard laboratory manuals, such as Davis et al., Basic Methods in Molecular Biology (1986) 30 and Sambrook et al.,[supra]. Particularly suitable methods include calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, WO 2004/113379 PCT/GB2004/002641 28 ballistic introduction or infection (see Samnbrook et al., 1989 [supra]; Ausubel et al., 1991 [supra]; Spector, Goldman & Leinwald, 1998). In eukaryotic cells, expression systems may either be transient (for example, episomal) or permanent (chromosomal integration) according to the needs of the system. 5 The encoding nucleic acid molecule may or may not include a sequence encoding a control sequence, such as a signal peptide or leader sequence, as desired, for example, for secretion of the translated polypeptide into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals. 10 Leader sequences can be removed by the bacterial host in post-translational processing. In addition to control sequences, it may be desirable to add regulatory sequences that allow for regulation of the expression of the polypeptide relative to the growth of the host cell. Examples of regulatory sequences are those which cause the expression of a 15 gene to be increased or decreased in response to a chemical or physical stimulus, including the presence of a regulatory compound or to various temperature or metabolic conditions. Regulatory sequences are those non-translated regions of the vector, such as enhancers, promoters and 5' and 3' untranslated regions. These interact with host cellular proteins to carry out transcription and translation. Such regulatory 20 sequences may vary in their strength and specificity. Depending on the vector system and host utilised, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the Bluescript phagemid (Stratagene, LaJolla, CA) or pSportlTM plasmid (Gibco BRL) 25 and the like may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (for example, heat shock, RUBISCO and storage protein genes) or from plant viruses (for example, viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are 30 preferable. If it is necessary to generate a cell line that contains multiple copies of the sequence, vectors based on SV40 or EBV may be used with an appropriate selectable marker. An expression vector is constructed so that the particular nucleic acid coding WO 2004/113379 PCT/GB2004/002641 29 sequence is located in the vector with the appropriate regulatory sequences, the positioning and orientation of the coding sequence with respect to the regulatory sequences being such that the coding sequence is transcribed under the "control" of the regulatory sequences, i.e., RNA polymerase which binds to the DNA molecule at 5 the control sequences transcribes the coding sequence. In some cases it may be necessary to modify the sequence so that it may be attached to the control sequences with the appropriate orientation; i.e., to maintain the reading frame. The control sequences and other regulatory sequences may be ligated to the nucleic acid coding sequence prior to insertion into a vector. Alternatively, the coding 10 sequence can be cloned directly into an expression vector that already contains the control sequences and an appropriate restriction site. For long-termn, high-yield production of a recombinant polypeptide, stable expression is preferred. For example, cell lines which stably express the polypeptide of interest may be transformed using expression vectors which may contain viral origins of 15 replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells that successfully 20 express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type. Mammalian cell lines available as hosts for expression are known in the art and include many immortalised cell lines available from the American Type Culture Collection (ATCC) including, but not limited to, Chinese hamster ovary (CHO), 25 HeLa, baby hamster kidney (BHK), monkey kidney (COS), C127, 3T3, BHK, HEK 293, Bowes melanoma and human hepatocellular carcinoma (for example Hep G2) cells and a number of other cell lines. In the baculovirus system, the materials for baculovirus/insect cell expression systems are commercially available in kit form from, inter alia, Invitrogen, San Diego CA (the 30 "MaxBac" kit). These techniques are generally known to those skilled in the art and are described fully in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987). Particularly suitable host cells for use in this system include WO 2004/113379 PCT/GB2004/002641 30 insect cells such as Drosophila S2 and Spodoptera Sf9 cells. There are many plant cell culture and whole plant genetic expression systems known in the art. Examples of suitable plant cellular genetic expression systems include those described in US 5,693,506; US 5,659,122; and US 5,608,143. Additional examples of 5 genetic expression in plant cell culture has been described by Zenk, Phytochemistry 30, 3861-3863 (1991). In particular, all plants from which protoplasts can be isolated and cultured to give whole regenerated plants can be utilised, so that whole plants are recovered which contain the transferred gene. Practically all plants can be regenerated from cultured 10 cells or tissues, including but not limited to all major species of sugar cane, sugar beet, cotton, fruit and other trees, legumes and vegetables. Examples of particularly preferred bacterial host cells include Streptococci, Staphylococci, E. coli, Streptomyces and Bacillus subtilis cells. Examples of particularly suitable host cells for fungal expression include yeast cells 15 (for example, S. cerevisiae) and Aspergillus cells. Any number of selection systems are known in the art that may be used to recover transformed cell lines. Examples include the herpes simplex virus thymidine kinase (Wigler, M. et al. (1977) Cell 11:223-32) and adenine phosphoribosyltransferase (Lowy, I. et al. (1980) Cell 22:817-23) genes that can be employed in tk- or aprt± 20 cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dihydrofolate reductase (DHFR) that confers resistance to methotrexate (Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. 77:3567-70); npt, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin, F. 25 et al (1981) J. Mol. Biol. 150:1-14) and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. Additional selectable genes have been described, examples of which will be clear to those of skill in the art. Although the presence or absence of marker gene expression suggests that the gene of 30 interest is also present, its presence and expression may need to be confirmed. For example, if the relevant sequence is inserted within a marker gene sequence, transformed cells containing the appropriate sequences can be identified by the WO 2004/113379 PCT/GB2004/002641 31 absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding a polypeptide of the invention under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well. 5 Alternatively, host cells that contain a nucleic acid sequence encoding a polypeptide of the invention and which express said polypeptide may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassays, for example, fluorescence activated cell sorting (FACS) or immunoassay techniques 10 (such as the enzyme-linked inmunosorbent assay [ELISA] and radioinmmunoassay [RIA]), that include membrane, solution, or chip based technlmologies for the detection and/or quantification of nucleic acid or protein (see Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St Paul, MN) and Maddox, D.E. etal. (1983) J. Exp. Med, 158, 1211-1216). 15 A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labelled hybridization or PCR probes for detecting sequences related to nucleic acid molecules encoding polypeptides of the present invention include oligolabelling, nick translation, end-labelling or PCR amplification using a labelled 20 polynucleotide. Alternatively, the sequences encoding the polypeptide of the invention may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesise RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3 or SP6 and labelled nucleotides. These procedures may be conducted using 25 a variety of commercially available kits (Pharmacia & Upjohn, (Kalamazoo, MI); Promega (Madison WI); and U.S. Biochemical Corp., Cleveland, OH)). Suitable reporter molecules or labels, which may be used for ease of detection, include radionuclides, enzymes and fluorescent, chemiluminescent or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like. 30 Nucleic acid molecules according to the present invention may also be used to create transgenic animals, particularly rodent animals. Such transgenic animals form a further aspect of the present invention. This may be done locally by modification of WO 2004/113379 PCT/GB2004/002641 32 somatic cells, or by germ line therapy to incorporate heritable modifications. Such transgenic animals may be particularly useful in the generation of animal models for drug molecules effective as modulators of the polypeptides of the present invention. The polypeptide can be recovered and purified from recombinant cell cultures by 5 well-known methods including ammonium sulphate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. High performance liquid chromatography is particularly useful for purification. Well known techniques for 10 refolding proteins may be employed to regenerate an active conformation when the polypeptide is denatured during isolation and or purification. Specialised vector constructions may also be used to facilitate purification of proteins, as desired, by joining sequences encoding the polypeptides of the invention to a nucleotide sequence encoding a polypeptide domain that will facilitate purification of 15 soluble proteins. Examples of such purification-facilitating domains include metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilised metals, protein A domains that allow purification on immobilised immunoglobulin, and the domain utilised in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, WA). The inclusion of cleavable linker 20 sequences such as those specific for Factor XA or enterokinase (Invitrogen, San Diego, CA) between the purification domain and the polypeptide of the invention may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing the polypeptide of the invention fused to several histidine residues preceding a thioredoxin or an enterokinase cleavage site. The 25 histidine residues facilitate purification by IMAC (immobilised metal ion affinity chromatography as described in Porath, J. et al. (1992), Prot. Exp. Purif. 3: 263-281) while the thioredoxin or enterokinase cleavage site provides a means for purifying the polypeptide from the fusion protein. A discussion of vectors which contain fusion proteins is provided in Kroll, D.J. et al. (1993; DNA Cell Biol. 12:441-453). 30 If the polypeptide is to be expressed for use in screening assays, generally it is preferred that it be secreted into the culture medium of the host cell in which it is expressed. In this event, the polypeptides of the invention may be purified from the culture medium may be harvested prior to use in the screening assay, for example WO 2004/113379 PCT/GB2004/002641 33 using standard protein purification techniques such as gel exclusion chromatography, ion-exchange chromatography or affinity chromatography. Examples of suitable methods of protein purification are provided in the Examples herein. If polypeptide is produced intracellularly, the cells must first be lysed before the polypeptide is 5 recovered. Alternatively, it may be preferred that the polypeptides of the invention be expressed as cell-surface fusion proteins. In this event, the host cells may be harvested prior to use in the screening assay, for example using techniques such as fluorescence activated cell sorting (FACs) or immunoaffinity techniques. 10 The polypeptide of the invention can be used to screen libraries of compounds in any of a variety of drug screening techniques. Such compounds may activate (agonise) or inhibit (antagonise) the level of expression of the gene or the activity of the polypeptide of the invention and form a further aspect of the present invention. Preferred compounds are effective to alter the expression of a natural gene which 15 encodes a polypeptide of the first aspect of the invention or to regulate the activity of a polypeptide of the first aspect of the invention. Agonist or antagonist compounds may be isolated from, for example, cells, cell-free preparations, chemical libraries or natural product mixtures. These agonists or antagonists may be natural or modified substrates, ligands, enzymes, receptors or 20 structural or functional mimetics. For a suitable review of such screening techniques, see Coligan et al., Current Protocols in Immunology l(2):Chapter 5 (1991). Compounds that are most likely to be good antagonists are molecules that bind to the polypeptide of the invention without inducing the biological effects of the polypeptide upon binding to it. Potential antagonists include small organic molecules, peptides, 25 polypeptides and antibodies that bind to the polypeptide of the invention and thereby inhibit or extinguish its activity. In this fashion, binding of the polypeptide to normal cellular binding molecules may be inhibited, such that the normal biological activity of the polypeptide is prevented. The polypeptide of the invention that is employed in such a screening technique may 30 be free in solution, affixed to a solid support, borne on a cell surface or located intracellularly. In general, such screening procedures may involve using appropriate cells or cell membranes that express the polypeptide that are contacted with a test WO 2004/113379 PCT/GB2004/002641 34 compound to observe binding, or stimulation or inhibition of a functional response. The functional response of the cells contacted with the test compound is then compared with control cells that were not contacted with the test compound. Such an assay may assess whether the test compound results in a signal generated by 5 activation of the polypeptide, using an appropriate detection system. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist in the presence of the test compound is observed. A preferred method for identifying a ligand for the IFNy-like polypeptides of the present invention comprises: 10 (a) contacting a cell expressing on the surface thereof a putative binding partner for a IFN-like polypeptide of the invention, the putative binding partner being capable of providing a detectable signal in response to the binding of a polypeptide of the present invention, (or associated with a second component capable of providing a detectable signal in response to the binding of a 15 polypeptide of the present invention), to the putative binding partner, with a polypeptide of the present invention to be screened under conditions to permit binding to the putative binding partner; and (b) determining whether the polypeptide of the present invention binds to and activates or inhibits the putative binding partner by measuring the level of a 20 signal generated from the interaction of the polypeptide of the present invention with the putative binding partner. A further preferred method for identifying a ligand for the IFNy-like polypeptides of the present invention comprises: (a) contacting a cell expressing on the surface thereof a putative binding partner 25 for a IFNy-like polypeptide of the invention, the putative binding partner being capable of providing a detectable signal in response to the binding of a polypeptide of the present invention, (or associated with a second component capable of providing a detectable signal in response to the binding of a polypeptide of the present invention), to the putative binding partner, with a 30 polypeptide of the present invention to permit binding to the putative binding partner; and (b) determining whether the polypeptide of the present invention binds to and WO 2004/113379 PCT/GB2004/002641 35 activates or inhibits the putative binding partner by comparing the level of a signal generated from the interaction of the polypeptide of the present invention with the putative binding partner with the level of a signal in the absence of the polypeptide of the present invention. 5 In further preferred embodiments, the general methods that are described above may further comprise conducting the identification of agonist or antagonist in the presence of labelled or unlabelled INSPO37 polypeptides. In another embodiment of the method for identifying an agonist or antagonist of a polypeptide of the present invention comprises: 10 determining the inhibition of binding of a polypeptide of the present invention to cells which have a ligand expressed at the surface thereof, or to cell membranes containing such a ligand, in the presence of a candidate compound under conditions to permit polypeptide binding to the ligand, and determining the amount of polypeptide bound to the ligand. A compound capable of causing reduction of binding of a polypeptide 15 of the present invention is considered to be an agonist or antagonist. Preferably the polypeptide of the invention is labelled. More particularly, a method of screening for an antagonist or agonist compound comprises the steps of: (a) incubating a labelled polypeptide of the present invention with a whole cell 20 expressing a ligand according to the invention on the cell surface, or a cell membrane containing a ligand of the invention, (b) measuring the amount of labelled polypeptide bound to the whole cell or the cell membrane; (c) adding a candidate compound to a mixture of labelled polypeptide and the 25 whole cell or the cell membrane of step (a) and allowing the mixture to attain equilibrium; (d) measuring the amount of labelled polypeptide bound to the whole cell or the cell membrane after step (c); and (e) comparing the difference in the labelled polypeptide bound in step (b) and (d), 30 such that the compound which causes the reduction in binding in step (d) is considered to be an agonist or antagonist.

WO 2004/113379 PCT/GB2004/002641 36 The polypeptides may be found to modulate a variety of physiological and pathological processes in a dose-dependent manner in the above-described assays. Thus, the "functional equivalents" of the polypeptides of the invention include polypeptides that exhibit any of the same modulatory activities in the above-described 5 assays in a dose-dependent manner. Although the degree of dose-dependent activity need not be identical to that of the polypeptides of the invention, preferably the "functional equivalents" will exhibit substantially similar dose-dependence in a given activity assay compared to the polypeptides of the invention. Alternatively, simple binding assays may be used, in which the adherence of a test 10 compound to a surface bearing the polypeptide is detected by means of a label directly or indirectly associated with the test compound or in an assay involving competition with a labelled competitor. In another embodiment, competitive drug screening assays may be used, in which neutralising antibodies that are capable of binding the polypeptide specifically compete with a test compound for binding. In this manner, 15 the antibodies can be used to detect the presence of any test compound that possesses specific binding affinity for the polypeptide. Assays may also be designed to detect the effect of added test compounds on the production of mRNA encoding the polypeptide in cells. For example, an ELISA may be constructed that measures secreted or cell-associated levels of polypeptide using 20 monoclonal or polyclonal antibodies by standard methods known in the art, and this can be used to search for compounds that may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues. The formation of binding complexes between the polypeptide and the compound being tested may then be measured. 25 Assay methods that are also included within the terms of the present invention are those that involve the use of the genes and polypeptides of the invention in overexpression or ablation assays. Such assays involve the manipulation of levels of these genes/polypeptides in cells and assessment of the impact of this manipulation event on the physiology of the manipulated cells. For example, such experiments 30 reveal details of signalling and metabolic pathways in which the particular genes/polypeptides are implicated, generate information regarding the identities of polypeptides with which the studied polypeptides interact and provide clues as to methods by which related genes and proteins are regulated.

WO 2004/113379 PCT/GB2004/002641 37 Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the polypeptide of interest (see International patent application WO84/03564). In this method, large numbers of different small test compounds are synthesised on a solid 5 substrate, which may then be reacted with the polypeptide of the invention and washed. One way of immobilising the polypeptide is to use non-neutralising antibodies. Bound polypeptide may then be detected using methods that are well known in the art. Purified polypeptide can also be coated directly onto plates for use in the aforementioned drug screening techniques. 10 The polypeptide of the invention may be used to identify membrane-bound or soluble receptors, through standard receptor binding techniques that are known in the art, such as ligand binding and crosslinking assays in which the polypeptide is labelled with a radioactive isotope, is chemically modified, or is fused to a peptide sequence that facilitates its detection or purification, and incubated with a source of the putative 15 receptor (for example, a composition of cells, cell membranes, cell supernatant, tissue extracts, or bodily fluids). The efficacy of binding may be measured using biophysical techniques such as surface plasmon resonance (supplied by Biacore AB, Uppsala, Sweden) and spectroscopy. Binding assays may be used for the purification and cloning of the receptor, but may also identify agonists and antagonists of the 20 polypeptide, that compete with the binding of the polypeptide to its receptor. Standard methods for conducting screening assays are well understood in the art. The invention also includes a screening kit useful in the methods for identifying agonists, antagonists, ligands, receptors, substrates, enzymes, that are described above. 25 The invention includes the agonists, antagonists, ligands, receptors, substrates and enzymes, and other compounds which modulate the activity or antigenicity of the polypeptide of the invention discovered by the methods that are described above. The invention also provides pharmaceutical compositions comprising a polypeptide, nucleic acid, ligand or compound of the invention in combination with a suitable 30 pharmaceutical carrier. These compositions may be suitable as therapeutic or diagnostic reagents, as vaccines, or as other immunogenic compositions, as outlined in detail below.

WO 2004/113379 PCT/GB2004/002641 38 According to the terminology used herein, a composition containing a polypeptide, nucleic acid, ligand or compound [X] is "substantially free of" impurities [herein, Y] when at least 85% by weight of the total X+Y in the composition is X. Preferably, X comprises at least about 90% by weight of the total of X+Y in the composition, more 5 preferably at least about 95%, 98% or even 99% by weight. The pharmaceutical compositions should preferably comprise a therapeutically effective amount of the polypeptide, nucleic acid molecule, ligand, or compound of the invention. The term "therapeutically effective amount" as used herein refers to an amount of a therapeutic agent needed to treat, ameliorate, or prevent a targeted 10 disease or condition, or to exhibit a detectable therapeutic or preventative effect. For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, for example, of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can 15 then be used to determine useful doses and routes for administration in humans. The precise effective amount for a human subject will depend upon the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. This amount can be determined by routine 20 experimentation and is within the judgement of the clinician. Generally, an effective dose will be from 0.01 mg/kg to 50 mg/kg, preferably 0.05 mg/kg to 10 mg/kg. Compositions may be administered individually to a patient or may be administered in combination with other agents, drugs or hormones. A pharmaceutical composition may also contain a pharmaceutically acceptable 25 carrier, for administration of a therapeutic agent. Such carriers include antibodies and other polypeptides, genes and other therapeutic agents such as liposomes, provided that the carrier does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity. Suitable carriers may be large, slowly metabolised macromolecules such as 30 proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers and inactive virus particles. Pharmaceutically acceptable salts can be used therein, for example, mineral acid salts WO 2004/113379 PCT/GB2004/002641 39 such as hydrochlorides, hydrobromides, phosphates, sulphates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of pharmaceutically acceptable carriers is available in Remington's Pharmaceutical Sciences (Mack Pub. Co., N.J. 1991). 5 Pharmaceutically acceptable carriers in therapeutic compositions may additionally contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such compositions. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, 10 slurries, suspensions, and the like, for ingestion by the patient. Once formulated, the compositions of the invention can be administered directly to the subject. The subjects to be treated can be animals; in particular, human subjects can be treated. The pharmaceutical compositions utilised in this invention may be administered by 15 any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal or transcutaneous applications (for example, see WO98/20734), subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, intravaginal or rectal means. Gene guns or hyposprays may also be used to administer the pharmaceutical 20 compositions of the invention. Typically, the therapeutic compositions may be prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. Direct delivery of the compositions will generally be accomplished by injection, 25 subcutaneously, intraperitoneally, intravenously or intramuscularly, or delivered to the interstitial space of a tissue. The compositions can also be administered into a lesion. Dosage treatment may be a single dose schedule or a multiple dose schedule. If the activity of the polypeptide of the invention is in excess in a particular disease state, several approaches are available. One approach comprises administering to a 30 subject an inhibitor compound (antagonist) as described above, along with a pharmaceutically acceptable carrier in an amount effective to inhibit the function of the polypeptide, such as by blocking the binding of ligands, substrates, enzymes, WO 2004/113379 PCT/GB2004/002641 40 receptors, or by inhibiting a second signal, and thereby alleviating the abnormal condition. Preferably, such antagonists are antibodies. Most preferably, such antibodies are chimeric and/or humanised to minimise their immunogenicity, as described previously. 5 In another approach, soluble forms of the polypeptide that retain binding affinity for the ligand, substrate, enzyme, receptor, in question, may be administered. Typically, the polypeptide may be administered in the form of fragments that retain the relevant portions. In an alternative approach, expression of the gene encoding the polypeptide can be 10 inhibited using expression blocking techniques, such as the use of antisense nucleic acid molecules (as described above), either internally generated or separately administered. Modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5' or regulatory regions (signal sequence, promoters, enhancers and introns) 15 of the gene encoding the polypeptide. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature (Gee, J.E. et al. 20 (1994) In: Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co., Mt. Kisco, NY). The complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes. Such oligonucleotides may be administered or may be generated in situ from expression in vivo. 25 In addition, expression of the polypeptide of the invention may be prevented by using ribozymes specific to its encoding mRNA sequence. Ribozymes are catalytically active RNAs that can be natural or synthetic (see for example Usman, N, et al., Curr. Opin. Struct. Biol (1996) 6(4), 527-33). Synthetic ribozymes can be designed to specifically cleave mRNAs at selected positions thereby preventing translation of the 30 mRNAs into functional polypeptide. Ribozymes may be synthesised with a natural ribose phosphate backbone and natural bases, as normally found in RNA molecules. Alternatively the ribozymes may be synthesised with non-natural backbones, for example, 2'-O-methyl RNA, to provide protection from ribonuclease degradation and WO 2004/113379 PCT/GB2004/002641 41 may contain modified bases. RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' 5 O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of non-traditional bases such as inosine, queosine and butosine, as well as acetyl-, methyl-, thio- and similarly modified forms of adenine, cytidine, guanine, thymine and uridine which are not as easily recognised 10 by endogenous endonucleases. For treating abnormal conditions related to an under-expression of the polypeptide of the invention and its activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound that activates the polypeptide, i.e., an agonist as described above, to 15 alleviate the abnormal condition. Alternatively, a therapeutic amount of the polypeptide in combination with a suitable pharmaceutical carrier may be administered to restore the relevant physiological balance of polypeptide. Gene therapy may be employed to effect the endogenous production of the polypeptide by the relevant cells in the subject. Gene therapy is used to treat 20 permanently the inappropriate production of the polypeptide by replacing a defective gene with a corrected therapeutic gene. Gene therapy of the present invention can occur in vivo or ex vivo. Ex vivo gene therapy requires the isolation and purification of patient cells, the introduction of a therapeutic gene and introduction of the genetically altered cells back into the patient. 25 In contrast, in vivo gene therapy does not require isolation and purification of a patient's cells. The therapeutic gene is typically "packaged" for administration to a patient. Gene delivery vehicles may be non-viral, such as liposomes, or replication-deficient viruses, such as adenovirus as described by Berkner, K.L., in Curr. Top. Microbiol. 30 Immunol., 158, 39-66 (1992) or adeno-associated virus (AAV) vectors as described by Muzyczka, N., in Curr. Top. Microbiol. Immunol., 158, 97-129 (1992) and U.S. Patent No. 5,252,479. For example, a nucleic acid molecule encoding a polypeptide of WO 2004/113379 PCT/GB2004/002641 42 the invention may be engineered for expression in a replication-defective retroviral vector. This expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding the polypeptide, such that the packaging cell now produces infectious viral particles 5 containing the gene of interest. These producer cells may be administered to a subject for engineering cells in vivo and expression of the polypeptide in vivo (see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited therein) in Human Molecular Genetics (1996), T Strachan and A P Read, BIOS Scientific Publishers Ltd). 10 Another approach is the administration of "naked DNA" in which the therapeutic gene is directly injected into the bloodstream or muscle tissue. In situations in which the polypeptides or nucleic acid molecules of the invention are disease-causing agents, the invention provides that they can be used in vaccines to raise antibodies against the disease causing agent. 15 Vaccines according to the invention may either be prophylactic (ie. to prevent infection) or therapeutic (ie. to treat disease after infection). Such vaccines comprise immunising antigen(s), immunogen(s), polypeptide(s), protein(s) or nucleic acid, usually in combination with pharmaceutically-acceptable carriers as described above, which include any carrier that does not itself induce the production of antibodies 20 harmful to the individual receiving the composition. Additionally, these carriers may ftmunction as immunostimulating agents ("adjuvants"). Furthermore, the antigen or immunogen may be conjugated to a bacterial toxoid, such as a toxoid from diphtheria, tetanus, cholera, H. pylori, and other pathogens. Since polypeptides may be broken down in the stomach, vaccines comprising 25 polypeptides are preferably administered parenterally (for instance, subcutaneous, intramuscular, intravenous, or intradermal injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient, and aqueous and non-aqueous 30 sterile suspensions which may include suspending agents or thickening agents. The vaccine formulations of the invention may be presented in unit-dose or multi dose containers. For example, sealed ampoules and vials and may be stored in a WO 2004/113379 PCT/GB2004/002641 43 freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation. Genetic delivery of antibodies that bind to polypeptides according to the invention 5 may also be effected, for example, as described in International patent application WO98/55607. The technology referred to as jet injection (see, for example, www.powderject.com) may also be useful in the formulation of vaccine compositions. A number of suitable methods for vaccination and vaccine delivery systems are 10 described in International patent application WO00/29428. This invention also relates to the use of nucleic acid molecules according to the present invention as diagnostic reagents. Detection of a mutated form of the gene characterised by the nucleic acid molecules of the invention which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a 15 disease, or susceptibility to a disease, which results from under-expression, over expression or altered spatial or temporal expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques. Nucleic acid molecules for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may 20 be used directly for detection or may be amplified enzymatically by using PCR, ligase chain reaction (LCR), strand displacement amplification (SDA), or other amplification techniques (see Saiki et al., Nature, 324, 163-166 (1986); Bej, et al., Crit. Rev. Biochem. Molec. Biol., 26, 301-334 (1991); Birkemneyer et al., J. Virol. Meth., 35, 117-126 (1991); Van Brunt, J., Bio/Technology, 8, 291-294 (1990)) prior 25 to analysis. In one embodiment, this aspect of the invention provides a method of diagnosing a disease in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide according to the invention and comparing said level of expression to a control level, wherein a level that is different to said control level is 30 indicative of disease. The method may comprise the steps of: a) contacting a sample of tissue from the patient with a nucleic acid probe under stringent conditions that allow the formation of a hybrid complex between a WO 2004/113379 PCT/GB2004/002641 44 nucleic acid molecule of the invention and the probe; b) contacting a control sample with said probe under the same conditions used in step a); c) and detecting the presence of hybrid complexes in said samples; 5 wherein detection of levels of the hybrid complex in the patient sample that differ from levels of the hybrid complex in the control sample is indicative of disease. A further aspect of the invention comprises a diagnostic method comprising the steps of: a) obtaining a tissue sample from a patient being tested for disease; 10 b) isolating a nucleic acid molecule according to the invention from said tissue sample; and c) diagnosing the patient for disease by detecting the presence of a mutation in the nucleic acid molecule which is associated with disease. To aid the detection of nucleic acid molecules in the above-described methods, an 15 amplification step, for example using PCR, may be included. Deletions and insertions can be detected by a change in the size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labelled RNA of the invention or alternatively, labelled antisense DNA sequences of the invention. Perfectly-matched sequences can be 20 distinguished from mismatched duplexes by RNase digestion or by assessing differences in melting temperatures. The presence or absence of the mutation in the patient may be detected by contacting DNA with a nucleic acid probe that hybridises to the DNA under stringent conditions to form a hybrid double-stranded molecule, the hybrid double-stranded molecule having an unhybridised portion of the nucleic acid 25 probe strand at any portion corresponding to a mutation associated with disease; and detecting the presence or absence of an unhybridised portion of the probe strand as an indication of the presence or absence of a disease-associated mutation in the corresponding portion of the DNA strand. Such diagnostics are particularly useful for prenatal and even neonatal testing. 30 Point mutations and other sequence differences between the reference gene and WO 2004/113379 PCT/GB2004/002641 45 "mutant" genes can be identified by other well-known techniques, such as direct DNA sequencing or single-strand conformational polymorphism, (see Orita et al., Genomics, 5, 874-879 (1989)). For example, a sequencing primer may be used with double-stranded PCR product or a single-stranded template molecule generated by a 5 modified PCR. The sequence determination is performed by conventional procedures with radiolabelled nucleotides or by automatic sequencing procedures with fluorescent-tags. Cloned DNA segments may also be used as probes to detect specific DNA segments. The sensitivity of this method is greatly enhanced when combined with PCR. Further, point mutations and other sequence variations, such as 10 polymorphisms, can be detected as described above, for example, through the use of allele-specific oligonucleotides for PCR amplification of sequences that differ by single nucleotides. DNA sequence differences may also be detected by alterations in the electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct 15 DNA sequencing (for example, Myers et al., Science (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton et al., Proc. Natl. Acad. Sci. USA (1985) 85: 4397-4401). In addition to conventional gel electrophoresis and DNA sequencing, mutations such 20 as microdeletions, aneuploidies, translocations, inversions, can also be detected by in situ analysis (see, for example, Keller et al., DNA Probes, 2nd Ed., Stockton Press, New York, N.Y., USA (1993)), that is, DNA or RNA sequences in cells can be analysed for mutations without need for their isolation and/or immobilisation onto a membrane. Fluorescence in situ hybridization (FISH) is presently the most commonly 25 applied method and numerous reviews of FISH have appeared (see, for example, Trachuck et al., Science, 250, 559-562 (1990), and Trask et al., Trends, Genet., 7, 149-154 (1991)). In another embodiment of the invention, an array of oligonucleotide probes comprising a nucleic acid molecule according to the invention can be constructed to 30 conduct efficient screening of genetic variants, mutations and polymorphisms. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability (see for example: M.Chee et al., Science WO 2004/113379 PCT/GB2004/002641 46 (1996), Vol 274, pp 610-613). In one embodiment, the array is prepared and used according to the methods described in PCT application WO95/11995 (Chee et al); Lockhart, D. J. et al. (1996) Nat. Biotech. 14: 1675-1680); and Schena, M. et al. (1996) Proc. Natl. Acad. Sci. 93: 5 10614-10619). Oligonucleotide pairs may range from two to over one million. The oligomers are synthesized at designated areas on a substrate using a light-directed chemical process. The substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any other suitable solid support. In another aspect, an oligonucleotide may be synthesized on the surface of the substrate by using a 10 chemical coupling procedure and an ink jet application apparatus, as described in PCT application W095/251116 (Baldeschweiler et al). In another aspect, a "gridded" array analogous to a dot (or slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such as those described above, 15 may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536 or 6144 oligonucleotides, or any other number between two and over one million which lends itself to the efficient use of commercially-available instrumentation. 20 In addition to the methods discussed above, diseases may be diagnosed by methods comprising determining, from a sample derived from a subject, an abnormally decreased or increased level of polypeptide or mRNA. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid 25 amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determnnine levels of a polypeptide of the present invention in a sample derived from a host are well-known to those of skill in the art and are discussed in some detail above (including radioimmunoassays, competitive 30 binding assays, Western Blot analysis and ELISA assays). This aspect of the invention provides a diagnostic method which comprises the steps of: (a) contacting a ligand as described above with a biological sample under conditions suitable for the formation of a ligand-polypeptide complex; and (b) detecting said complex.

WO 2004/113379 PCT/GB2004/002641 47 Protocols such as ELISA, RIA, and FACS for measuring polypeptide levels may additionally provide a basis for diagnosing altered or abnormal levels of polypeptide expression. Normal or standard values for polypeptide expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, 5 preferably humans, with antibody to the polypeptide under conditions suitable for complex formation The amount of standard complex formation may be quantified by various methods, such as by photometric means. Antibodies which specifically bind to a polypeptide of the invention may be used for the diagnosis of conditions or diseases characterised by expression of the polypeptide, 10 or in assays to monitor patients being treated with the polypeptides, nucleic acid molecules, ligands and other compounds of the invention. Antibodies useful for diagnostic purposes may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for the polypeptide include methods that utilise the antibody and a label to detect the polypeptide in human body fluids or extracts of cells 15 or tissues. The antibodies may be used with or without modification, and may be labelled by joining them, either covalently or non-covalently, with a reporter molecule. A wide variety of reporter molecules known in the art may be used, several of which are described above. Quantities of polypeptide expressed in subject, control and disease samples from 20 biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease. Diagnostic assays may be used to distinguish between absence, presence, and excess expression of polypeptide and to monitor regulation of polypeptide levels during therapeutic intervention. Such assays may also be used to evaluate the efficacy of a particular 25 therapeutic treatment regimen in animal studies, in clinical trials or in monitoring the treatment of an individual patient. A diagnostic kit of the present invention may comprise: (a) a nucleic acid molecule of the present invention; (b) a polypeptide of the present invention; or 30 (c) a ligand of the present invention. In one aspect of the invention, a diagnostic kit may comprise a first container containing a nucleic acid probe that hybridises under stringent conditions with a WO 2004/113379 PCT/GB2004/002641 48 nucleic acid molecule according to the invention; a second container containing primers useful for amplifying the nucleic acid molecule; and instructions for using the probe and primers for facilitating the diagnosis of disease. The kit may further comprise a third container holding an agent for digesting unhybridised RNA. 5 In an alternative aspect of the invention, a diagnostic kit may comprise an array of nucleic acid molecules, at least one of which may be a nucleic acid molecule according to the invention. To detect polypeptides according to the invention, a diagnostic kit may comprise one or more antibodies that bind to a polypeptide according to the invention; and a reagent 10 useful for the detection of a binding reaction between the antibody and the polypeptide. Such kits will be of use in diagnosing a disease or susceptibility to disease, particularly immune disorders, such as autoimmune disease, rheumatoid arthritis, osteoarthritis, psoriasis, systemic lupus erythematosus, and multiple sclerosis, 15 myastenia gravis, Guillain-Barr6 syndrome, Graves disease, autoimmune alopecia, sclerodemnna, psoriasis (Kimball et al., Arch Dermatol 2002 Oct:138(10):1341-6) and graft-versus-host disease (Miura Y., et al., Blood 2002 Oct 1:100(7):2650-8), monocyte and neutrophil dysfunction, attenuated B cell function, inflammatory disorders, such as acute inflammation, septic shock, asthma, anaphylaxis, eczema, 20 dermatitis, allergy, rhinitis, conjunctivitis, glomerulonephritis, uveitis, Sjogren's disease (Anaya et al., J Rheumatol 2002 Sep; 29(9):1874-6), Crohn's disease (Schmit A. et al., Eur Cytokine Netw 2002 Jul-Sep:13(3):298-305), ulcerative colitis, inflammatory bowel disease, pancreatitis, digestive system inflammation, ulcerative colitis, sepsis, endotoxic shock, septic shock, cachexia, myalgia, ankylosing 25 spondylitis, myasthenia gravis, post-viral fatigue syndrome, pulmonary disease, respiratory distress syndrome, asthma, chronic-obstructive pulmonary disease, airway inflammation, wound healing, type I and type II diabetes, endometriosis, dermatological disease, Beheet's disease, hmmuno-deficiency disorders, chronic lung disease (Oei J et al., Acta Paediatr 2002:91(11):1194-9), aggressive and chronic 30 periodontitis (Gonzales JR, et al., J clin Periodontol 2002 Sep:29(9):816-22), cancers including carcinomas, sarcomas, lymphomas, renal tumour, colon tumour, Hodgkin's disease, melanomas, such as metastatic melanomas (Vaishampayan U, Clin Cancer WO 2004/113379 PCT/GB2004/002641 49 Res 2002 Dec:8(12):3696-701), mesotheliomas, Burkitt's lymphoma, neuroblastoma, haematological disease, nasopharyngeal carcinomas, leukemias, myelomas, myeloproliferative disorder and other neoplastic diseases, osteoporosis, obesity, diabetes, gout, cardiovascular disorders, reperfusion injury, atherosclerosis, ischaemic 5 heart disease, cardiac failure, stroke, liver disease such as chronic hepatitis (Semin Liver Dis 2002:22 Suppl 1:7), AIDS (Dereuddre-Bosquet N., et al., J Acquir Immune Defic Syndr Hum Retroviol 1996 Mar 1: 11(3):241-6), AIDS related complex, neurological disorders, fibrotic diseases, male infertility, ageing and infections, including plasmodium infection, bacterial infection, fungal diseases, such as 10 ringworm, histoplasmosis, blastomycosis, aspergillosis, cryptococcosis, sporotrichosis, coccidioidocomycosis, paracoccidiomycosis and candidiasis, diseases associated with antimicrobial immunity (Bogdan, Current Opinion in Immunology 2000, 12:419-424), Peyronie's disease (Lacy et al., Int J Impot Res 2002 Oct:14(5):336-9), tuberculosis (Dieli et al., J Infect Dis 2002 Dec 15;186(12):1835-9), 15 and viral infection (Pfeffer LM, Semin Oncol 1997 Jun 24:S9-63-69). Various aspects and embodiments of the present invention will now be described in more detail by way of example, with particular reference to INSPO37 polypeptides. It will be appreciated that modification of detail may be made without departing from the scope of the invention. 20 Brief description of the Figures Figure 1: Results from Inpharmatica Genome Threader query using SEQ ID NO:2. Figure 2: Alignment generated by Inpharmatica Genome Threader between SEQ ID NO:2 and closest related structure. Figure 3: INSP037 predicted nucleotide sequence (comprising SEQ ID NO:l1) with 25 translation (SEQ ID NO:2). Figure 4: INSPO37 cloned nucleotide sequence (comprising SEQ ID NO: 1) with translation (SEQ ID NO:2), demonstrating that the predicted and cloned sequence for INSP037 are identical. Figure 5: Map of PCRII-TOPO-IPAAA44548. 30 Figure 6: Map of expression vector pEAK12d. Figure 7: Map of plasmid pDONR201.

WO 2004/113379 PCT/GB2004/002641 50 Figure 8: Map of expression vector pEAK12d-IPAAA44548-6HIS. Figure 9: Map of E. coli expression vector pDEST14. Figure 10: Map of plasmid pDEST14-IPAAA44548-6HIS. Figure 11: Nucleotide sequence of PCRII-TOPO-IPAAA44548. 5 Figure 12: Nucleotide sequence ofpDEST14-IPAAA44548-6HIS. Figure 13: Nucleotide sequence ofpEAK12D-IPAAA44548-6HIS. Figure 14: The NCBI-NR results for INSPO37 (SEQ ID NO:2) showing no 100% match, thus demonstrating INSPO37 to be novel. Figure 15: The NCBI-month-aa results for INSPO37 (SEQ ID NO:2) showing no 100% 10 match, thus demonstrating INSP037 to be novel. Figure 16A: The translated nucleotide database NCBI-month-nt results for INSP037 (SEQ ID NO:2) showing no 100% match, thus demonstrating INSPO37 to be novel. Figure 16B: The NCBI-nt results for INSPO37 (SEQ ID NO:2) showing no 100% match, thus demonstrating INSPO37 to be novel. 15 Figure 17: Results of an investigation of INSPO37 activity in a murine model of ConA induced fulminant hepatitis. Figure 18: Positive control showing effects of IL-6 upon a murine model of ConA induced fulminant hepatitis. Examples 20 Example 1: Identification of INSPO37 The polypeptide sequence derived from SEQ ID NO:2 which represents the translation of exons from INSPO37 was used as a query in the Inpharmatica Genome Threader tool against protein structures present in the PDB database. The top match is the structure of a four helical bundle cytokine family member. The top match aligns to 25 the query sequence with a Genome Threader confidence of 84% (Figure 1). Figure 2 shows the alignment of the INSPO37 query sequence to the sequence of Bovine interferon-gamma (PDB-1ld9g) a member of the four helical bundle cytokine family (Randal et al Acta Crystallogr D Biol Crystallogr. 2000 Jan;56 (Pt 1):14-24). Note that the INSPO37 polypeptide sequence is referred to as "IPAAA445" in Figure 2.

WO 2004/113379 PCT/GB2004/002641 51 Members of the four helical bundle cytokine family of proteins are of therapeutic importance. Figure 16B shows that INSPO37 can be found on Homo sapiens chromosome 3. As described above, all Type I interferons are clustered on chromosome 9. Therefore, the 5 location of the INSP037 gene on chromosome 3 ( 3 q25.33, chr3:157121275 157121511 (on hgl5/build 33)) is in accordance with its annotation herein as an IFN gamma like interferon, and thus as a Type II interferon. Example 2: Cloning of INSPO37 (IPAAA44548) from eDNA libraries cDNA libraries 10 Human cDNA libraries (in bacteriophage lambda (1) vectors) were purchased from Stratagene or Clontech or prepared at the Serono Pharmaceutical Research Institute in X ZAP or k GT10 vectors according to the manufacturer's protocol (Stratagene). Bacteriophage X DNA was prepared from small scale cultures of infected E.coli host strain using the Wizard Lambda Preps DNA purification system according to the 15 manufacturer's instructions (Promega, Corporation, Madison WI.) The list of libraries and host strains used is shown in Table 1. Table 1: Human cDNA libraries Library Tissuelcell source Vector Host strain Supplier Cat. no. 1 human fetal brain Zap II XL1-Blue MRF' Stratagene 936206 2 human ovary GT10 LE392 Clontech HL1098a 3 human pituitary GTI10 LE392 Clontech HL1097a 4 human placenta GT11 LE392 Clontech HL1075b 5 human testis GT11 LE392 Clontech HL1010b 6 human sustanta nigra GT10 LE392 in house 7 human fetal brain GT10 LE392 in house 8 human cortex brain GT1O LE392 in house 9 human colon GT10 LE392 Clontech HL1034a 10 human fetal brain GT10 LE392 Clontech HL1065a 11 human fetal lung GT10 LE392 Clontech HL1072a WO 2004/113379 PCT/GB2004/002641 52 12 human fetal kidney GT10 LE392 Clontech HL1071a 13 human fetal liver GT10 LE392 Clontech HL1064a 14 human bone marrow GT10 LE392 Clontech HL1058a 15 human peripheral blood monocytes GT10 LE392 Clontech HL1050a 16 human placenta GT10 LE392 in house 17 human SHSYSY GT10 LE392 in house 18 human U373 cell line GT10 LE392 in house 19 human CFPoc-1 cell line Uni Zap XL1-Blue MRF' Stratagene 936206 20 human retina GT10 LE392 Clontech HL1132a 21 human urinary bladder GT10 LE392 in house 22 human platelets Uni Zap XL1-Blue MRF' in house 23 human neuroblastoma Kan + TS GT10 LE392 in house 24 human bronchial smooth muscle GT10 LE392 in house 25 human bronchial smooth muscle GT10 LE392 in house 26 human Thymus GT10 LE392 Clontech HL1127a 27 human spleen 5' stretch GT11 LE392 Clontech HL1134b 28 human peripherical blood monocytes GT10 LE392 Clontech HL1050a 29 human testis GT10 LE392 Clontech HL1065a 30 human fetal brain GT10 LE392 Clontech HL1065a 31 human substancia Nigra GT10 LE392 Clontech HL1093a 32 human placenta#11 GT11 LE392 Clontech HL1075b 33 human Fetal brain GT10 LE392 Clontech custom 34 human placenta #59 GT10 LE392 Clontech HL5014a 35 human pituirary GT10 LE392 Clontech HL1097a 36 human pancreas #63 Uni Zap XR XL1-Blue MRF' Stratagene 937208 37 human placenta #19 GT 11 LE392 Clontech HL1008 38 human liver 5'strech GT 11 LE392 Clontech HL1115b 39 human uterus Zap-CMVXR XL1-Blue MRF' Stratagene 980207 40 human kidney large-insert cDNA library TriplEx2 XL1-Blue Clontech HL5507u WO 2004/113379 PCT/GB2004/002641 53 Gene specific cloning primers for PCR Pairs of PCR primers having a length of between 18 and 25 bases were designed for amplifying the full length sequence of the virtual cDNA using Primer Designer Software, as shown in Table 2 below (Scientific & Educational Software, PO Box 5 72045, Durham, NC 27722-2045, USA). PCR primers were optimized to have a Tm close to 55 + 10 oC and a GC content of 40-60%. Primers were selected which had high selectivity for the target sequence IPAAA44548 (little or no none specific priming). Table II: INSPO37 Cloning primers Primer Name Sequence (5'-3') Position TmoC %GC CP1 2C5 GCA TCA ACA ACA TCC AGT AA 28 58 40 Forward primer CP2 2C6 CAT TCT AAA GTG TGC CAT CT 291C 57 40 Reverse Primer 10 PCR of virtual cDNAs from phage library DNA Full-length virtual cDNA encoding IPAAA44548 (Figure 3) was obtained as a PCR amplification product of 264 bp (Figure 4) using gene specific cloning primers (CP 1 and CP2, Figure 3 and Table 2). The PCR was performed in a final volume of 50p1l containing lX AmpliTaq T M buffer, 200 tM dNTPs, 50 pmoles each of cloning 15 primers primers, 2.5 units of AmpliTaq T M (Perkin Elmer) and 100 ng of each phage library DNA using an MJ Research DNA Engine, programmed as follows: 94 OC, 1 min; 40 cycles of 94 oC, 1 min, x OC, and y min and 72 OC, (where x is the lowest Tm - 5 oC andy = 1 min per kb of product); followed by 1 cycle at 72 oC for 7 min and a holding cycle at 4 oC. 20 The amplification products were visualized on 0.8 % agarose gels in 1 X TAE buffer (Life Technologies) and PCR products migrating at the predicted molecular mass were purified from the gel using the Wizard PCR Preps DNA Purification System (Promega). PCR products eluted in 50 pl of sterile water were either sub-cloned directly or stored at -20 oC.

WO 2004/113379 PCT/GB2004/002641 54 Subcloning of PCR Products PCR products were subcloned into the topoisomerase I modified cloning vector (pCR II TOPO) using the TOPO TA cloning kit purchased from the Invitrogen Corporation (cat. No. K4600-01 and K4575-01 respectively) using the conditions specified by the 5 manufacturer. Briefly, 4 Vl of gel purified PCR product from the human pituitary library (library number 3) amplification was incubated for 15 min at room temperature with 1 tl of TOPO vector and 1 ~l salt solution. The reaction mixture was then transformed into E. coli strain TOP10 (Invitrogen) as follows: a 50 pl aliquot of One Shot TOP10 cells was thawed on ice and 2 p1 of TOPO reaction was 10 added. The mixture was incubated for 15 min on ice and then heat shocked by incubation at 42 OC for exactly 30 s. Samples were returned to ice and 250 pVl of warm SOC media (room temperature) was added. Samples were incubated with shaking (220 rpm) for 1 h at 37 oC. The transformation mixture was then plated on L-broth (LB) plates containing ampicillin (100 tg/ml) and incubated overnight at 37 oC. 15 Ampicillin resistant colonies containing cDNA inserts were identified by colony PCR. Colony PCR Colonies were inoculated into 50 pl sterile water using a sterile toothpick. A 10 Ll aliquot of the inoculum was then subjected to PCR in a total reaction volume of 20 pl as described above, except the primers pairs used were SP6 (5') and T7. The cycling 20 conditions were as follows: 94 'C, 2 min; 30 cycles of 94 'C, 30 sec, 47 OC, 30 sec and 72 'C for 1 min); 1 cycle, 72 'C, 7 min. Samples were then maintained at 4 OC (holding cycle) before further analysis. PCR reaction products were analyzed on 1 % agarose gels in 1 X TAE buffer. Colonies which gave the expected PCR product size (264 bp cDNA + 187 bp due to 25 the multiple cloning site or MCS) were grown up overnight at 37 oC in 5 ml L-Broth (LB) containing ampicillin (50 pg /ml), with shaking at 220 rpm at 37 oC. Plasmid DNA preparation and Sequencing Miniprep plasmid DNA was prepared from 5 ml cultures using a Qiaprep Turbo 9600 robotic system (Qiagen) or Wizard Plus SV Minipreps kit (Promega cat. no. 1460) WO 2004/113379 PCT/GB2004/002641 55 according to the manufacturer's instructions. Plasmid DNA was eluted in 100 p1 of sterile water. The DNA concentration was measured using an Eppendorf BO photometer. Plasmid DNA (200-500 ng) was subjected to DNA sequencing with T7 primer and SP6 primer using the BigDyeTerminator system (Applied Biosystems cat. 5 no. 4390246) according to the manufacturer's instructions. Sequencing reactions were purified using Dye-Ex columns (Qiagen) or Montage SEQ 96 cleanup plates (Millipore cat. no. LSKS09624) then analyzed on an Applied Biosystems 3700 sequencer. Example 3: Construction of plasmids for expression of INSPO37 (IPAAA44548) in 10 HEK293/EBNA cells A pCRII-TOPO clone containing the full coding sequence (ORF) of IPAAA44548 identified by DNA sequencing (Figure 5) was then used to subclone the insert into the mammalian cell expression vector pEAK12d (Figure 6) using the Gateway T M cloning methodology (Invitrogen). The cloned sequence contains a single nucleotide 15 substitution A134G (Figure 4). Generation of Gateway compatible IPAAA44548 ORF fused to an in frame 6HIS tag sequence. The first stage of the Gateway cloning process involves a two step PCR reaction which generates the ORF of IPAAA44548 flanked at the 5' end by an attB1 20 recombination site and Kozak sequence, and flanked at the 3' end by a sequence encoding an in frame 6 histidine (6HIS) tag, a stop codon and the attB2 recombination site (Gateway compatible eDNA). The first PCR reaction (in a final volume of 50 jul) contains: 25 ng of pCR II TOPO-IPAAA44548 (plasmid 13124 and Figure 5), 2 pl dNTPs (5mM), 5p1 of o10X Pfx polymerase buffer, 0.5 p1 each of gene 25 specific primer (100 gM) (EX1 forward and EX1 reverse) and 0.5 pl Platinum Pfx DNA polymerase (Invitrogen). The PCR reaction was performed using an initial denaturing step of 95 0 C for 2 min, followed by 12 cycles of 94 oC, 15 sec and 68 0 C for 30 sec. PCR products were purified directly from the reaction mixture using the Wizard PCR prep DNA purification system (Promega) according to the 30 manufacturer's instructions. The second PCR reaction (in a final volume of 50 p1) contained 10 pl purified PCR product, 2 pl dNTPs (5 mM), 5 pl of O10X Pfx WO 2004/113379 PCT/GB2004/002641 56 polymerase buffer, 0.5 pl of each Gateway conversion primer (100 ptM) (GCP forward and GCP reverse) and 0.5 pl of Platinum Pfx DNA polymerase. The conditions for the 2nd PCR reaction were: 95 oC for 1 min; 4 cycles of 94 oC, 15 sec; 45 oC, 30 sec and 68 OC for 3.5 min; 25 cycles of 94 oC, 15 sec; 55 oC, 30 sec and 68 5 oC, 3.5 min. PCR products were purified as described above. Alternatively for expression of IPAAA44548 in E.coli, an ORF was generated which contained a Shine Dalgarno sequence upstream of the initiating methionine codon using gene specific primers (EX3 - forward and EX2 - reverse) in the first PCR, and primers GCPF and GCPR using the same conditions as described above. The resultant 10 PCR product was called SD-IPAAA44548. Subcloning of Gateway compatible IPAAA44548 ORF into Gateway entry vector pDONR201 and expression vector pEAK12d The second stage of the Gateway cloning process involves subcloning of the Gateway modified PCR product into the Gateway entry vector pDONR201 15 (Invitrogen, Figure 7) as follows: 5 jil of purified PCR product is incubated with 1.5 pl pDONR201 vector (0.1 pg/ptl), 2 p1 BP buffer and 1.5 pl of BP clonase enzyme mix (Invitrogen) at RT for 1 h. The reaction was stopped by addition of proteinase K (2 pg) and incubated at 37 0 C for a further 10 min. An aliquot of this reaction (2 pl) was transformed into E. coli DH10B cells by electroporation using a Biorad Gene 20 Pulser. Transformants were plated on LB-kanamycin plates. Plasmid mini-prep DNA was prepared from 1-4 of the resultant colonies using Wizard Plus SV Minipreps kit (Promega), and 1.5 pl of the plasmid eluate was then used in a recombination reaction containing 1.5 pl pEAK12d vector (Figure 6) (0.1 [tg / p l), 2 il LR buffer and 1.5 p1tl of LR clonase (Invitrogen) in a final volume of 10 pl. The mixture was incubated at 25 RT for 1 h, stopped by addition of proteinase K (2 pg) and incubated at 37 0 C for a further 10 min. An aliquot of this reaction (1 pl) was used to transform E. coli D OH10B cells by electroporation. Clones containing the correct insert were identified by performing colony PCR as described above except that pEAK12d primers (pEAK12d F and pEAK12d R) were 30 used for the PCR. Plasmid mini prep DNA was isolated from clones containing the correct insert using a Qiaprep Turbo 9600 robotic system (Qiagen) or manually using WO 2004/113379 PCT/GB2004/002641 57 a Wizard Plus SV minipreps kit (Promega) and sequence verified using the pEAK12d F and pEAK12d R primers. CsCl gradient purified maxi-prep DNA of plasmid pEAK12d-IPAAA44548-6HIS (plasmid ID number 11775, Figure 8) was prepared from a 500 ml culture of sequence 5 verified clones (Sambrook J. et al., in Molecular Cloning, a Laboratory Manual, 2 nd edition, 1989, Cold Spring Harbor Laboratory Press), resuspended at a concentration of 1 pg/Il in sterile water and stored at -20 C. Construction of expression vector pEAK12d The vector pEAK12d is a Gateway Cloning System compatible version of the 10 mammalian cell expression vector pEAKl2 (purchased from Edge Biosystems) in which the cDNA of interest is expressed under the control of the human EFlat promoter. pEAK12d was generated as described below: pEAK12 was digested with restriction enzymes HindlIIl and NotI, made blunt ended with Klenow (New England Biolabs) and dephosphorylated using calf-intestinal 15 alkaline phosphatase (Roche). After dephosphorylation, the vector was ligated to the blunt ended Gateway reading frame cassette C (Gateway vector conversion system, Invitrogen cat no. 11828-019) which contains AttR recombination sites flanking the ccdB gene and chloramphenicol resistance, and transformed into E.coli DB3.1 cells (which allow propagation of vectors containing the ccdB gene). Mini prep DNA was 20 isolated from several of the resultant colonies using a Wizard Plus SV Minipreps kit (Promega) and digested with Asel / EcoRI to identify clones yielding a 670 bp fragment, indicating that the cassette had been inserted in the correct orientation. The resultant plasmid was called pEAK12d (Figure 6). Subcloning of Gateway compatible SD - IPAAA44548 ORF into Gateway entry 25 vector pDONR201 and E.coli expression vector pDEST14. Gateway compatible SD-IPAAA44548 ORF containing an in frame 3' 6HIS tag coding sequence and a 5' upstream Shine Dalgarno sequence was subcloned into pDONR201 using BP clonase. The resultant plasmid was then used in a recombination reaction with the E.coli expression vector pDEST14 (purchased from 30 Invitrogen, Figure 9) using LR clonase as described above. The resultant expression WO 2004/113379 PCT/GB2004/002641 58 plasmid (pDEST14-IPAAA44548-6HIS) (Figure 10, plasmid ID 12896) was sequence verified as described above. For expression in E.coli, CsC1 purified maxi prep DNA was re-transformed into E.coli host strain BL21. The expression of the inserted cDNA is under the control of a T7 promoter. 5 Table 3: Primers for IPAAA44548 subcloning and sequencing Primer Name Sequence (5'-3') GCP I-C1 attBl-K G GGG ACA AGT TTG TAC AAA AAA GCA GGC TTC Forward GCC ACC GCP 22A3 attB2-stop-His6- GGG GAC CAC TTT GTA CAA GAA AGC TGG GTT TCA Reverse R ATG GTG ATG GTG ATG GTG GCP-SD III-Al attBl- G GGG ACA AGT TTG TAC AAA AAA GCA GGC TTC Forward shineDalgarno-p GCA GA G EXI 32A5 attBlp- GCA GGC TTC GCC ACC ATG ACT TCA CCA AAC GAA Forward IPAAA44548-1F CTA A EX2 32A8 IPAAA44548- GTG ATG GTG ATG GTG AAG TGT GCC ATC TGC ATT Reverse H6p-234R TCT EX3 II-18 AAA GCA GGC TTC GAA_ GGA GAT ATA CAT ATG ACT forward 44548ShineDalgarno-1F TCA CCA AAC GAA CT pEAK12-F 32D1 GCC AGC TTG GCA CTT GAT GT pEAK12-R 32D2 GAT GGA GGT GGA CGT GTC AG SP6 ATT TAG GTG ACA CTA TAG T7 TAA TAC GAC TCA CTA TAG GG pDEST14-R TGG CAG CAG CCA ACT CAG CTT Underlined sequence = Kozak sequence Bold = Stop codon Italic sequence = His tag Shaded sequence = Shine Dalgarno sequence (Ribosome binding site) WO 2004/113379 PCT/GB2004/002641 59 Example 4: Identification of cDNA libraries containing IPAAA44548 PCR products obtained with CP1 and CP2 and migrating at the correct size (264 bp) were identified in libraries 3, 8 and 12 (pituitary, brain cortex and fetal kidney respectively). 5 Example 5: Expression in mammalian cells of the cloned, IPAAA44548-S-6HIS (plasmid number 12118) Cell culture Human Embryonic Kidney 293 cells expressing the Epstein-Barr virus Nuclear Antigen (HEK293-EBNA, Invitrogen) were maintained in suspension in Ex-cell 10 VPRO serum-fr-ee medium (seed stock, maintenance medium, JRH). Sixteen to 20 hours prior to transfection (Day-1), cells were seeded in 2x T225 flasks (50 ml per flask in DMEM / F12 (1:1) containing 2% FBS seeding medium (JRH) at a density of 2xl 05 cells/ ml). The next day (transfection day0) the transfection took place by using the JetPEI T m reagent (2pl/pg of plasmid DNA, PolyPlus-transfection). For each flask, 15 113 ptg of plasmid (No. 12118) was co-transfected with 2.3 pg of GFP (fluorescent reporter gene). The transfection mix was then added to the 2xT225 flasks and incubated at 37 0 C (5%CO 2 ) for 6 days. Confirmation of positive transfection was done by qualitative fluorescence examination at day 1 and day 6 (Axiovert 10 Zeiss). 20 On day 6 (harvest day), supernatants (100ml) from the two flasks were pooled and centrifuged (4'C, 400g) and placed into a pot bearing a unique identifier. One aliquot (500ul) was kept for QC of the 6His-tagged protein (internal bioprocessing QC). Scale-up batches were produced following the protocol called "PEI transfection of 25 suspension cells" referenced BP / PEI/ HH/02/04 with PolyEthylenelmine from Polysciences as transfection agent. This protocol was based on the following proportions: WO 2004/113379 PCT/GB2004/002641 60 For 400 ml spinner: 1E6 hek293EBNA cells / ml in 200ml FEME 1% FBS 400 pig (plasmid No. 12118) diluted into 10 ml FEME 1% and 800ug PEI added 90 minutes post-transfection, FEME 1% medium added to reach 400-ml total volume. Spinner left in culture for 6 days until harvest. 5 Purification process The culture medium sample (100 or 400 ml) containing the recombinant protein with a C-terminal 6His tag was diluted with one volume cold buffer A (50 mM NaH 2

PO

4 ; 600 mM NaC1; 8.7 % (w/v) glycerol, pH 7.5) to a final volume of 200 and 800 ml, respectively. The sample was filtered through a 0.22 um sterile filter (Millipore, 500 10 ml filter unit) and kept at 4oC in a sterile square media bottle (Nalgene). The purification was performed at 4oC on the VISION workstation (Applied Biosystems) connected to an automatic sample loader (Labomatic). The purification procedure was composed of two sequential steps, metal affinity chromatography on a Poros 20 MC (Applied Biosystems) column charged with Ni ions (4.6 x 50 mm, 0.83 15 ml), followed by gel filtration on a Sephadex G-25 medium (Amersham Pharnnacia) column (1,0 x 10 cm). For the first chromatography step the metal affinity column was regenerated with 30 column volumes of EDTA solution (100 mM EDTA; 1 M NaCl; pH 8.0), recharged with Ni ions through washing with 15 column volumes of a 100 mM NiSO 4 solution, 20 washed with 10 column volumes of buffer A, followed by 7 column volumes of buffer B (50 mM NaH 2

PO

4 ; 600 mM NaC1; 8.7 % (w/v) glycerol, 400 mM; imidazole, pH 7.5), and finally equilibrated with 15 column volumes of buffer A containing 15 mM imidazole. The sample was transferred, by the Labomatic sample loader, into a 200 ml sample loop and subsequently charged onto the Ni metal affinity 25 column at a flow rate of 10 ml/min. In case of the 400 ml scale up samples the transfer and charging procedure was repeated 4 times. The column was subsequently washed with 12 colunmi volumes of buffer A, followed by 28 column volumes of buffer A containing 20 mM imidazole. During the 20 mM imidazole wash loosely attached contaminating proteins were elution of the column. The recombinant His- WO 2004/113379 PCT/GB2004/002641 61 tagged protein was finally eluted with 10 column volumes of buffer B at a flow rate of 2 ml/mnin, and the eluted protein was collected in a 1.6 ml fraction. For the second chromatography step, the Sephadex G-25 gel-filtration column was regenerated with 2 ml of buffer D (1.137 M NaCl; 2.7 mM KC1; 1.5 mM KH 2

PO

4 ; 8 5 mM Na 2

HPO

4 ; pH 7.2), and subsequently equilibrated with 4 column volumes of buffer C (137 mM NaCl; 2.7 mM KCI; 1.5 mM KH 2

PO

4 ; 8 mM Na 2

HPO

4 ; 20 % (w/v) glycerol; pH 7.4). The peak fraction eluted from the Ni-column was automatically through the integrated sample loader on the VISION loaded onto the Sephadex G-25 column and the protein was eluted with buffer C at a flow rate of 2 10 ml/min. The desalted sample was recovered in a 2.2 ml fraction. The fraction was filtered through a 0.22 um sterile centrifugation filter (Millipore), frozen and stored at -80C. An aliquot of the sample was analyzed on SDS-PAGE (4-12 % NuPAGE gel; Novex) by coomassie staining and Western blot with anti-His antibodies. Coomassie staining. The NuPAGE gel was stained in a 0.1 % coomassie blue R250 15 staining solution (30 % methanol, 10 % acetic acid) at room temperature for 1 h and subsequently destained in 20 % methanol, 7.5 % acetic acid until the background was clear and the protein bands clearly visible. Western blot. Following the electrophoresis the proteins were electrotransferred from the gel to a nitrocellulose membrane at 290 mA for 1 hour at 4 0 C. The membrane was 20 blocked with 5 % milk powder in buffer E (137 mM NaC1; 2.7 mM KCl; 1.5 mM

KH

2 PO4; 8 mM Na 2

HPO

4 ; 0.1 % Tween 20, pH 7.4) for 1 h at room temperature, and subsequently incubated with a mixture of 2 rabbit polyclonal anti-His antibodies (G 18 and H-15, 0.2ug/ml each; Santa Cruz) in 2.5 % milk powder in buffer E overnight at 4 0 C. After further 1 hour incubation at room temperature, the membrane was 25 washed with buffer E (3 x 10 min), and then incubated with a secondary HRP conjugated anti-rabbit antibody (DAKO, HRP 0399) diluted 1/3000 in buffer E containing 2.5 % milk powder for 2 hours at room temperature. After washing with buffer E (3 x 10 minutes), the membrane was developed with the ECL kit (Amersham Pharmacia) for 1 min. The membrane was subsequently exposed to a Hyperfilm 30 (Amersham Pharmacia), the film developed and the western blot image visually analysed.

WO 2004/113379 PCT/GB2004/002641 62 Protein assay. The protein concentration was determined using the BCA protein assay kit (Pierce) with bovine serum albumin as standard in samples that showed detectable protein bands by coomassie staining. Expression of IPAAA44548-SEC- 6HIS in bacterial cells (plasmid No. 12896) 5 The method below describes the use of E. Coli BL-21 DE3 bacterial strain for producing the protein. "BL21 DE3" are part of T7 RNA polymerase-based expression systems widely used for over-expressing recombinant proteins. Transformation of bacterial strain BL21 (DE3): We used the procedure of TSS method, the protocol has been taken from: Chung, C.T 10 et al., Proc. Natl. Acad. Sci. USA (1989) 86:2172-2175. 10-100 ng DNA (2 [l) of the recombinant plasmid No. 12896 were added to competent BL21 for TSS method and placed 20 minutes on ice. SOC medium (0.8 ml) were added and the tube was incubated at 37'C, 200 rpm for 1 hour. From this culture 20 pl and 200 Itl were sampled and plated on LB plates containing Ampicillin 15 (40 ptg/ml final concentration) and left overnight at 37 0 C. The next day, 3 colonies were isolated and used for preparation of the glycerol stocks, tested for expression in shake flasks experiments before transferring production into a fernnenter (one out of the three was chosen for large scale, as they were all performing the same in shake flasks). 20 Preparation of a seed stock for long term storage of the recombinant E Coli strain: A 5 ml tube containing LB medium with Ampicillin 40 pg/ml (final concentration) was inoculated with a single colony from a fresh agar plate. Bacteria were grown overnight at 37 C, 200 rpm. The next morning, 50 pl of the overnight culture was sampled in order to inoculate a fresh 5 ml LB tube (+ antibiotics) and incubated 2-3 25 hours at 37 0 C, 200 rpm in order to bring bacteria to the exponential growth phase. 5 ml glycerol at 20 % was then added to the culture and mixed. 1.5 ml were dispensed in each of 5 cryogenic vials which constitute a seed stock stored at -80'C (internal Glycerol stock).

WO 2004/113379 PCT/GB2004/002641 63 Expression at the 5-litre scale: The recombinant strain was propagated in a 5-litres Biolafitte stirred tank reactor (working containing 5-litres of ECPM 1 medium (having a composition as reported in Table 4) with appropriate antibiotic (40 pg/ml final concentration) and 0.5 % Glucose 5 in order to avoid pre-induction of the T7 promoter. Only The research-grade run 2464 was prepared and sent to purification. The inoculum was prepared in a 500-ml LB (+ antibiotics, 0.5 % Glucose) shake flask starting from one loop of frozen bacteria (scraped from one of the glycerol seed stock vial) and grown for 9 hours before automatic inoculation. When cells reached 10 OD 10, (usually after 7 to 9 hours growth), the protein production was induced with IPTG: 1 mM final concentration. Induction lasted 3 hours. Fermenter setting conditions throughout growth and induction were set at: 50 % dissolved oxygen concentration, 300 to 700 rpm depending on pO2, pH7.0. The PO2 was maintained by air sparging +/- 02 at 25 ml/min. A 5-ml sample was taken every 15 hour and optical density was measured at 600 nm. The cells were harvested and centrifuged at 4 000 rpm (in Sorvall RC 3B). The pellet was kept frozen at -20 'C until further processing. Presence of the protein in the cells extract was assessed by Coomassie staining of a SDS-PAGE. 20 Table 4: ECPM1 composition Component Source Comment Cone. Unit Steril. Type CaCl2.2H20 STOCK SOL. stock sol.=1.32 g/1 10 ml/1 HT MAIN CAS.AA Sigma Enzymatic Hydrolysate 20 g/1 HT MAIN GLYCEROL 0.87 or anhydrous glycerol 46 g/1 HT MAIN K2HPO4 STOCK-SOL. stock sol. = 400 g/l 10 mI/I HT MAIN K2SO4 STOCK SOL Stock Sol=104 g/1 22.7 ml/1 HT MAIN KHI-12PO4 STOCK SOL. stock sol.= 100 g/1 10 ml/l HT MAIN MgCl2.6H20 stock sol Stock Sol= IM 2 ml/i FI ADD N4C1 STOCK SOL. stock sol.= 100 g/l 10 mI/l HT MAIN WO 2004/113379 PCT/GB2004/002641 64 TRACE STOCK SOL. stock sol composition in 10 ml HT MAIN Elements (see TRACE I Y.E Difco 3 g/l HT MAIN A few drops of Antifoam PPG P2000 are added. Table 5: Trace Elements Component Comment Cone Unit Steril. Type Amonium molb adjust pH 7-8 as necessary 0.01 g/l HT MAIN Co(NO3)26H20 0.01 g/1 HT MAIN CuC12 2H20 0.01 g/1 HT MAIN EDTA dissolved in approx.800ml 5 g/1 HT MAIN FeC13 6H20 0.5 g/1 FI MAIN ZnO 0.05 g/l HT MAIN Each element was separately dissolved in HC1. Purification process 5 67 g of the frozen bacteria paste was suspended in 270 ml of buffer A (50 mM NaH 2

PO

4 ; 600 mM NaCl; 1 mM PMSF; 1 mM benzamidine; 8.7 % (w/v) glycerol, pH 7.5) supplemented with 1 tablet of complete EDTA-free protease inbitors (Roche) /50 ml. The bacteria were disrupted by two passages through the Z-plus cell disrupter (Constant Cell Disruption Systems) at 1300 bar. 10 The sample was subsequently centrifuged at 36,000 x g for 30 min. The supernatant (300 ml) was loaded, at a flow rate of 4 ml/min, onto a Ni-NTA-Agarose column (2.5 x 3.0 cm) equilibrated in buffer A. The column was washed with 100 ml buffer A followed by 85 ml 20 mM imidazole in buffer A. Proteins were eluted at a flow rate of 3 ml/min by a 300 ml linear gradient 15 of 20 to 250 mM imidazole in buffer A and fractions of 7.5 ml were collected. A sample of every second fraction was diluted 1/6 in reducing SDS-sample buffer, 15 ul loaded /well on a 4-12 % NuPage gel (Novex) and after electrophoresis the gel was stained with coomassie blue. Fractions with the highest IPAAA44548 concentration (fractions 36-42) were pooled, 20 total volume was 53 ml (Pool N1). Fractions on both sides of pool N1 with a lower WO 2004/113379 PCT/GB2004/002641 65 purity and concentration (fractions 32-35 + 43-44) were pooled into pool N2 with a volume of 44 ml. The pools from the Ni-column were further purified on a Q-Sepharose Fast flow column (1.5 x 12 cm) equilibrated in buffer B (50 mM Tris-HC1, 1 mM benzamidine, 5 pH 7.5). 52 ml of pool N1 was diluted with 300 ml buffer B and 648 ml H20 to a final volume of 1000 ml. The sample was loaded onto the column at a flow rate of 5 ml/min, the column washed with 150 ml buffer B and proteins were eluted with a 160 ml linear gradient of 0 to 400 mM NaCl in buffer B. Fractions of 2 ml were collected and analyzed by coomassie stained SDS-PAGE as described above. Fractions 28-30 10 (Pool Q1) contained one protein band at the expected molecular weight of 9.6 kDa. Fractions 31-33 (Pool Q2) in addition contained a protein band at approximately 20 kDa, indicating dimer formation. 43 ml of pool N2 from the Ni-column was diluted with 300 ml buffer B and 657 ml

H

2 0 to 1000 ml. The sample was loaded onto the Q-Sepharose column, the protein 15 was eluted and fractions analyzed as described for pool N1. Fractions 28-30 (Pool Q3) contained one protein band at the expected molecular weight of 9.6 kDa. Each Q-pool had a volume of 5.5 ml. The pools from the Q-Sepharose column were passed over a Superdex G75 gel filtration column (HiLoad 16/60, Pharmacia). The column was washed with 0.5 M 20 NaOH and equilibrated in PBS. The column was run at a flow rate of 1 ml/min and 5 ml of the pools was loaded onto the column. Fractions of 2 ml were collected and analyzed by coomassie stained SDS-PAGE as described above. IPAAA44548 from pool Q1 eluted in fractions 31-35 (9.5 ml) (Sl), from pool Q2 the protein eluted in two peaks, in fraction 31-34 (7.5 ml) (S2) and in fractions 26-28 (5.8 25 ml) (S3), and the protein in pool Q3 eluted in fractions 32-35 (7.5 ml) (S4). When analyzed on non-reducing SDS-PAGE pool S3 showed to contain over 80 % of the protein as dimers, whereas the other pools contained only traces of dimers. The pools S1 and S2 had comparable purity and concentration and were pooled into one pool Slb (9.5+7.5=17 ml). 30 Protein concentrations were determined by measuing absorption at 280 nm, using the calculated molar extinction coefficient of 7,090 and molecular weight of 9,625. The WO 2004/113379 PCT/GB2004/002641 66 molecular mass of the protein, determined by mass spectrometry, was found to be 9,624.6 in pools Slb and S4. The molecular mass in pool S3 was determined to be 19,252.2, confirming disulphide bridged dimers in this pool. The pools were assayed for LPS and contained between 1.1 and 3.4 U/mg. 5 Summary of the purified pools: Pool Concentration Total amount Lot number Pool Slb 2.1 mg/ml 35.7 mg 2 Pool S3 1.7 mg/ml 9.8 mg 3 Pool S4 0.95 mg/ml 7.1 mg 6 10 A total of 52 mg pure protein was recovered, or 0.77 mg/g bacteria paste. All three pools were over 97 % pure on RP-HPLC. Example 6: In vivo characterisation of IPAA44548 (INSPO37) The IPAA44548 (INSPO37) protein (IPAAA44548-6-HIS and IPAAA44548-ATT 6HIS) was shown in vitro to induce IFNy secretion by Concanavalin A (ConA) and 15 Phytohemagglutinin (PHA)-stimulated human peripheral blood mononuclear cells (hPBMC) (preliminary data, not shown). On the basis of those data, it was decided to test the activity of IPAAA44548 (INSPO37) in an in vivo ConA model by electrotransfer, as described below. Concanavalin A (ConA)-induced liver hepatitis 20 Toxic liver disease represents a worldwide health problem in humans for which pharmacological treatments have yet to be discovered. For example, active chronic hepatitis leading to liver cirrhosis is a disease state, in which liver parenchymal cells are progressively destroyed by activated T cells. ConA-induced liver toxicity is one of three experimental models of T-cell dependent apoptotic and necrotic liver injury 25 described in mice. Gal N (D-Galactosamine) sensitized mice challenged with either activating anti-CD3 monoclonal AB or with superantigen SEB develop severe apoptotic and secondary necrotic liver injury (Kusters S, Gastroenterology. 1996 Aug;111(2):462-71). Injection of the T-cell mitogenic plant lectin ConA to non- WO 2004/113379 PCT/GB2004/002641 67 sensitized mice results also in hepatic apoptosis that preceeds necrosis. ConA induces the release of systemic TNFu and IFNy and various other cytokines. Both TNFe and IFNy are critical mediators of liver injury. Transaminase release 8 hours after the insult indicates severe liver destruction. 5 Several cell types have been shown to be involved in liver damage, including CD4 T cells, macrophages and natural killer cells (Kaneko J Exp Med 2000, 191, 105-114). Anti-CD4 antibodies block activation of T cells and consequently liver damage (Tiegs et al. 1992, J Clin Invest 90, 196-203). Pre-treatment of mice with monoclonal antibodies against CD8 failed to protect, whereas deletion of macrophages prevented 10 the induction of hepatitis. A study was undertaken to investigate the role of IPAA44548, a IFNy like protein, in ConA-induced liver hepatitis. Several cytokines have been shown either to be critical in inducing or in conferring protection from ConA-induced liver damage. TNFc for example is one of the first cytokines produced after ConA injection and anti-TNFc 15 antibodies confer protection against disease (Seino et al. 2001, Annals of surgery 234, 681). IFNy appears also to be a critical mediator of liver injury, since anti-IFNy antiserum significantly protect mice, as measured by decreased levels of transaminases in the blood of ConA-treated animals (see Kusters et al., above). In liver injury, increased production of IFNy was observed in patients with autoimmune 20 or viral hepatitis. In addition transgenic mice expressing IFNy in the liver develop liver injury resembling chronic active hepatitis (Toyonaga et al. 1994, PNAS 91, 614 618). IFNy may also be cytotoxic to hepatocytes, since in vitro IFNy induces cell death in mouse hepatocytes that was accelerated by TNF (Morita et al. 1995, Hepatology 21, 1585-1593). 25 Other molecules have been described to be protective in the ConA model. A single administration of rhIL-6 completely inhibited the release of transaminases (Mizuhara et al. 1994, J. Exp. Med. 179, 1529-1537). cDNA electrotransfer into muscle fibers in order to achieve systemic expression of a protein of interest 30 Among the non-viral techniques for gene transfer in vivo, the direct injection of WO 2004/113379 PCT/GB2004/002641 68 plasmid DNA into the muscle and subsequent electroporation is simple, inexpensive and safe. The post-mitotic nature and longevity of myofibers permits stable expression of transfected genes, although the transfected DNA does not usually undergo chromosomal integration (Somiari et al. 2000, Molecular Therapy 2,178). 5 Several reports have demonstrated that secretion of muscle-produced proteins into the blood stream can be achieved after electroporation of corresponding cDNAs (Rizzuto et al. PNAS, 1996, 6417; Aihara H et al., 1998, Nature Biotech 16, 867). In addition, in vivo efficacy of muscle expressed Epo and IL-18BP in disease models has been shown (Rizzuto, 2000, Human Gene Therapy 41, 1891; Mallat, 2001, Circulation 10 research 89, 41). The following material and methods were employed in this Example: Animals In all the studies male C57/BL6 male (8 weeks old) were used. In general, 7 animals per experimental group are used. Mice were maintained in standard conditions under 15 a 12-hour light-dark cycle, provided irradiated food and water ad libitum. Muscle Electrotransfer Choice ofvector His or StreplI tagged hlL-6 or IPAAA44548 genes were cloned in the Gateway compatible pDEST12.2 containing the CMV promoter. 20 Electroporation Protocol Mice were anaesthetised with gas (isofluran, Baxter, Ref: ZDG9623). Hindlimbs were shaved and an echo graphic gel was applied. Hyaluronidase was injected in the posterior tibialis mucle with (20U in 50 p1 sterile NaCl 0.9%, Sigma, Ref. H3631). After 10 min, 100 gg of plasmid (50 tg per leg in 25 Rl of sterile NaCl 0.9%) was 25 injected in the same muscle. The DNA was prepared in the Buffer PBS-L-Glutamate (6 mg/ml; L-Glutamate, Sigma, P4761) before intra-muscular injection. For electrotransfer, the electric field was applied for each leg with the ElectroSquarePorator (BTX, ref ECM830) at 75 Volts during 20 ms for each pulse, 10 pulses with an interval of 1 second in a unipolar way with 2 round electrodes (size 0.5 WO 2004/113379 PCT/GB2004/002641 69 mm diameter) (Mir LM et al, Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4262-7 and Haas K et al., Neuron. 2001 Mar;29(3):583-91.). Readouts Blood Sampling 5 100 p1 of blood was sampled from the eye at various 1.30h, 6h and 8h time-points. At the time of sacrifice, blood was taken from the heart. Detection of cytokines and transaminases in blood samples IL-2, IL-5, IL-4, TNFc and IFNy cytokine levels were measured using the TH1/TH2 CBA assay (BD 551287). ASpartate AminoTransferase (ASAT), ALanine Amino 10 Transferase ALAT and urea blood parameters were determnnined using the COBAS instrument (Hitachi). ConA induction Mice female C57/B16 (from IFFA CREDO), 8 weeks old animals; ConA (purchased from Sigma, ref.C7275). ConA was injected at different doses at time 0 i.v and blood 15 samples were taken at 1.30, 6 or 8 hours post-injection. Cytokine and ASAT ALAT measurements were performed like described above. IL-6 pretreatment in the ConA model CHO cell produced hIL-6 was injected 1 hour before ConA injection. IPAAA44548 and IL-6 electrotransfer 20 At day 0 electrotransfer of IPAAA44548 or hIL-6 vectors as well as the empty vector (negative control) was performed (according to the above protocol). At day 5 after electrotransfer, ConA (20mg/kg) was injected iv and blood sampled at 3 time-points (1.30, 6, 24 hours). Cytokines, ASAT and ALAT measurements were performed like described above. 25 Results In vivo, in this murine model of ConA-induced fulminant hepatitis, treatment using WO 2004/113379 PCT/GB2004/002641 70 cDNA electrotransfer with IPAAA44548 showed an increase in circulating levels of TNF-a, IL-2, and IFN-y (see Figure 17 A-C). In addition ASAT and ALAT levels were increased with respect to the control (Figure 17, D and E). Results in Figure 18 A-F represent the positive control of the experiment (rhIL-6 5 known to block pro-inflammatory response induced by ConA). We used either the pDEST12.2hIL-6-STREPII or the pDEST12.2 STREPII electrotransfer vectors in order to express hlL-6 in the blood and thus show subsequent protection from ConA induced liver toxicity. Our experiments show that expression of IPAAA44548 protein in serum using 10 electrotransfer increases the level of pro-inflammatory cytokines at a systemic level after ConA challenge and exacerbates liver disease as measured by increased transaminase levels. These results confirm the predicted IFN'y-like activity of IPAAA44548 and open a series of interesting therapeutic applications for the protein per se. For example, 15 known applications of IFNy may now be investigated for suitability to IPAAA44548 (e.g. anti-cancer activity). It will also now be possible to identify inhibitors or antagonists of IPAAA44548, such as for example monoclonal antibodies, which may be of use in further studies of IPAAA44548 activity in vivo or in clinical applications.

WO 2004/113379 PCT/GB2004/002641 71 INSPO37 Sequence Information: SEQ ID NO: 1 (Nucleotide sequence of INSP037) 1 ATGACTTCAC CAAACGAACT AAATAAGCTG CCATGGACCA ATCCTGGAGA 5 51 AACAGAGATA TGTGACCTTT CAGACACAGA ATTCAAAATA TCTGTGTTGA 101 AGAACCTCAA AGAAATTCAA GATAACACAG AGAAGGAATC CAGAATTCTA 151 TCAGACAAAT ATAAGAAACA GATTGAAATA ATTAAAGGGA ATCAAGCAGA 201 AATTCTGGAG TTGAGAAATG CAGATGGCAC ACTTTAG 10 SEQ ID NO: 2 (Protein sequence of INSP037) 1 MTSPNELNKL PWTNPGETEI CDLSDTEFKI SVLKNLKEIQ DNTEKESRIL 51 SDKYKKQIEI IKGNQAEILE LRNADGTL

Claims

1. A polypeptide, which polypeptide: (i) comprises or consists of the amino acid sequence as recited in SEQ ID NO:2; (ii) is a fragment thereof that is an interferon gamma-like secreted protein of the 5 four helical bundle cytokine fold, or having an antigenic determinant in common with the polypeptides of (i); or (iii) is a functional equivalent of (i) or (ii).

2. A polypeptide according to claim 1 which functions as an interferon gamma-like secreted protein of the four helical bundle cytokine fold. 10

3. A polypeptide which is a functional equivalent according to part (iii) of claim 1, is homologous to the amino acid sequence as recited in SEQ ID NO:2 and is an interferon gamma-like secreted protein of the four helical bundle cytokine fold.

4. A fragment or functional equivalent according to any one of the preceding claims, which has greater than 80% sequence identity with the amino acid sequence 15 recited in SEQ ID NO:2 or with active fragments thereof, preferably greater than 90%, 95%, 98% or 99% sequence identity.

5. A functional equivalent according to any one of the preceding claims, which exhibits significant structural homology with a polypeptide having the amino acid sequence given in SEQ ID NO:2. 20

6. A fragment as recited in any one of claims 1, 2 or 4 having an antigenic determinant in common with a polypeptide of part (i) of claim 1 which consists of 7 or more (for example, 8, 10, 12, 14, 16, 18, 20 or more) amino acid residues from the sequence of SEQ ID NO:2.

7. A purified nucleic acid molecule which encodes a polypeptide according to any 25 one of the preceding claims.

8. A purified nucleic acid molecule according to claim 7, which has the nucleic acid sequence as recited in SEQ ID NO: 1 or is a redundant equivalent or fragment thereof.

9. A purified nucleic acid molecule which hybridizes under high stringency 30 conditions with a nucleic acid molecule according to claim 7 or claim 8. WO 2004/113379 PCT/GB2004/002641 73

10. A vector comprising a nucleic acid molecule as recited in any one of claims 7-9.

11. A host cell transformed with a vector according to claim 10, a host cell according to claim 11.

12. A ligand which binds specifically to, and which preferably inhibits the interferon 5 gamma-like activity of, a polypeptide according to any one of claims 1-6.

13. A ligand according to claim 12, which is an antibody.

14. A compound that either increases or decreases the level of expression or activity of a polypeptide according to any one of claims 1-6.

15. A compound according to claim 14 that binds to a polypeptide according to any 10 one of claims 1-6 without inducing any of the biological effects of the polypeptide.

16. A compound according to claim 14 or claim 15, which is a natural or modified substrate, ligand, enzyme, receptor or structural or functional mimetic.

17. A polypeptide according to any one of claims 1-6, a nucleic acid molecule 15 according to any one of claims 7-9, a vector according to claim 10, a host cell according to claim 11, a ligand according to claim 12 or claim 13, or a compound according to any one of claims 14-16, for use in therapy or diagnosis of disease.

18. A method of diagnosing a disease in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide according to any one of 20 claims 1-6, or assessing the activity of a polypeptide according to any one of claims 1-6, in tissue from said patient and comparing said level of expression or activity to a control level, wherein a level that is different to said control level is indicative of disease.

19. A method according to claim 18 that is carried out in vitro. 25

20. A method according to claim 18 or claim 19, which comprises the steps of: (a) contacting a ligand according to claim 12 or claim 13 with a biological sample under conditions suitable for the formation of a ligand-polypeptide complex; and (b) detecting said complex.

21. A method according to claim 18 or claim 19, comprising the steps of: 30 a) contacting a sample of tissue from the patient with a nucleic acid probe under WO 2004/113379 PCT/GB2004/002641 74 stringent conditions that allow the formation of a hybrid complex between a nucleic acid molecule according to any one of claims 7-9 and the probe; b) contacting a control sample with said probe under the same conditions used in step a); and 5 c) detecting the presence of hybrid complexes in said samples; wherein detection of levels of the hybrid complex in the patient sample that differ from levels of the hybrid complex in the control sample is indicative of disease.

22. A method according to claim 18 or claim 19, comprising: a) contacting a sample of nucleic acid from tissue of the patient with a nucleic acid 10 primer under stringent conditions that allow the formation of a hybrid complex between a nucleic acid molecule according to any one of claims 7-9 and the primer; b) contacting a control sample with said primer under the same conditions used in step a); and 15 c) amplifying the sampled nucleic acid; and d) detecting the level of amplified nucleic acid from both patient and control samples; wherein detection of levels of the amplified nucleic acid in the patient sample that differ significantly from levels of the amplified nucleic acid in the control sample is indicative of disease. 20

23. A method according to claim 18 or claim 19 comprising: a) obtaining a tissue sample from a patient being tested for disease; b) isolating a nucleic acid molecule according to any one of claims 7-9 from said tissue sample; and c) diagnosing the patient for disease by detecting the presence of a mutation which is 25 associated with disease in the nucleic acid molecule as an indication of the disease.

24. The method of claim 23, further comprising amplifying the nucleic acid molecule to form an amplified product and detecting the presence or absence of a mutation in the amplified product. 30

25. The method of either claim 23 or 24, wherein the presence or absence of the WO 2004/113379 PCT/GB2004/002641 75 mutation in the patient is detected by contacting said nucleic acid molecule with a nucleic acid probe that hybridises to said nucleic acid molecule under stringent conditions to form a hybrid double-stranded molecule, the hybrid double-stranded molecule having an unhybridised portion of the nucleic acid probe strand at any 5 portion corresponding to a mutation associated with disease; and detecting the presence or absence of an umihybridised portion of the probe strand as an indication of the presence or absence of a disease-associated mutation.

26. A method according to any one of claims 18-25, wherein said disease is selected from immune disorders, such as autoimmune disease, rheumatoid arthritis, 10 osteoarthritis, psoriasis, systemic lupus erythematosus, and multiple sclerosis, myastenia gravis, Guillain-Barr6 syndrome, Graves disease, autoimmune alopecia, scleroderma, psoriasis and graft-versus-host disease, monocyte and neutrophil dysfunction, attenuated B cell function, inflammatory disorders, such as acute inflammation, septic shock, asthma, anaphylaxis, eczema, dermatitis, allergy, 15 rhinitis, conjunctivitis, glomerulonephritis, uveitis, Sjogren's disease, Crohn's disease, ulcerative colitis, inflammatory bowel disease, pancreatitis, digestive system inflammation, ulcerative colitis, sepsis, endotoxic shock, septic shock, cachexia, myalgia, ankylosing spondylitis, myasthenia gravis, post-viral fatigue syndrome, pulmonary disease, respiratory distress syndrome, asthma, chronic 20 obstructive pulmonary disease, airway inflammation, wound healing, type I and type II diabetes, endometriosis, dermatological disease, Beheet's disease, immuno-deficiency disorders, chronic lung disease, aggressive and chronic periodontitis, cancers including carcinomas, sarcomas, lymphomas, renal tumour, colon tumour, Hodgkin's disease, melanomas, such as metastatic melanomas, 25 mesotheliomas, Burkitt's lymphoma, neuroblastoma, haematological disease, nasopharyngeal carcinomas, leukemias, myelomas, myeloproliferative disorder and other neoplastic diseases, osteoporosis, obesity, diabetes, gout, cardiovascular disorders, reperfusion injury, atherosclerosis, ischaemic heart disease, cardiac failure, stroke, liver disease such as chronic hepatitis, AIDS, AIDS related 30 complex, neurological disorders, fibrotic diseases, male infertility, ageing and infections, including plasmodium infection, bacterial infection, fungal diseases, such as ringworm, histoplasmosis, blastomycosis, aspergillosis, cryptococcosis, sporotrichosis, coccidioidocomycosis, paracoccidiomycosis and candidiasis, WO 2004/113379 PCT/GB2004/002641 76 diseases associated with antimicrobial immunity, Peyronie's disease, tuberculosis, and viral infection.

27. Use of a polypeptide according to any one of claims 1-6 as an interferon gamma like secreted protein of the four helical bundle cytokine fold. 5

28. A pharmaceutical composition comprising a polypeptide according to any one of claims 1-6, a nucleic acid molecule according to any one of claims 7-9, a vector according to claim 10, a host cell according to claim 11, a ligand according to claim 11 or 12, or a compound according to any one of claims 14-16.

29. A vaccine composition comprising a polypeptide according to any one of claims 10 1-6 or a nucleic acid molecule according to any one of claims 7-9.

30. A polypeptide according to any one of claims 1-6, a nucleic acid molecule according to any one of claims 7-9, a vector according to claim 10, a host cell according to claim 11, a ligand according to claim 11 or 12, a compound according to any one of claims 14-16, or a pharmaceutical composition according 15 to claim 28, for use in the manufacture of a medicament for the treatment of a disease selected from immune disorders, such as autoimmune disease, rheumatoid arthritis, osteoarthritis, psoriasis, systemic lupus erythematosus, and multiple sclerosis, myastenia gravis, Guillain-Barr6 syndrome, Graves disease, autoimmune alopecia, scleroderma, psoriasis and graft-versus-host disease, 20 monocyte and neutrophil dysfunction, attenuated B cell function, inflammatory disorders, such as acute inflammation, septic shock, asthma, anaphylaxis, eczema, dermatitis, allergy, rhinitis, conjunctivitis, glomerulonephritis, uveitis, Sjogren's disease, Crohn's disease, ulcerative colitis, inflammatory bowel disease, pancreatitis, digestive system inflammation, ulcerative colitis, sepsis, endotoxic 25 shock, septic shock, cachexia, myalgia, ankylosing spondylitis, myasthenia gravis, post-viral fatigue syndrome, pulmonary disease, respiratory distress syndrome, asthma, chronic-obstructive pulmonary disease, airway inflammation, wound healing, type I and type II diabetes, endometriosis, dermatological disease, Behcet's disease, inmmnuno-deficiency disorders, chronic lung disease, aggressive 30 and chronic periodontitis, cancers including carcinomas, sarcomas, lymphomas, renal tumour, colon tumour, Hodgkin's disease, melanomas, such as metastatic melanomas, mesotheliomas, Burkitt's lymphoma, neuroblastoma, haematological WO 2004/113379 PCT/GB2004/002641 77 disease, nasopharyngeal carcinomas, leukemias, myelomas, myeloproliferative disorder and other neoplastic diseases, osteoporosis, obesity, diabetes, gout, cardiovascular disorders, reperfusion injury, atherosclerosis, ischaemic heart disease, cardiac failure, stroke, liver disease such as chronic hepatitis, AIDS, 5 AIDS related complex, neurological disorders, fibrotic diseases, male infertility, ageing and infections, including plasmodium infection, bacterial infection, fungal diseases, such as ringworm, histoplasmosis, blastomycosis, aspergillosis, cryptococcosis, sporotrichosis, coccidioidocomycosis, paracoccidiomycosis and candidiasis, diseases associated with antimicrobial immunity, Peyronie's disease, 10 tuberculosis, and viral infection.

31. A method of treating a disease in a patient, comprising administering to the patient a polypeptide according to any one of claims 1-6, a nucleic acid molecule according to any one of claims 7-9, a vector according to claim 10, a host cell according to claim 11, a ligand according to claim 11 or 12, or a compound 15 according to any one of claims 14-16, or a pharmaceutical composition according to claim 28.

32. A method according to claim 31, wherein, for diseases in which the expression of the natural gene or the activity of the polypeptide is lower in a diseased patient when compared to the level of expression or activity in a healthy patient, the 20 polypeptide, nucleic acid molecule, vector, ligand, compound or composition administered to the patient is an agonist.

33. A method according to claim 31, wherein, for diseases in which the expression of the natural gene or activity of the polypeptide is higher in a diseased patient when compared to the level of expression or activity in a healthy patient, the 25 polypeptide, nucleic acid molecule, vector, ligand, compound or composition administered to the patient is an antagonist.

34. A method of monitoring the therapeutic treatment of disease in a patient, comprising monitoring over a period of time the level of expression or activity of a polypeptide according to any one of claims 1-6, or the level of expression of a 30 nucleic acid molecule according to any one of claims 7-9 in tissue from said patient, wherein altering said level of expression or activity over the period of time towards a control level is indicative of regression of said disease. WO 2004/113379 PCT/GB2004/002641 78

35. A method for the identification of a compound that is effective in the treatment and/or diagnosis of disease, comprising contacting a polypeptide according to any one of claims 1-6, or a nucleic acid molecule according to any one of claims 7-9 with one or more compounds suspected of possessing binding affinity for said 5 polypeptide or nucleic acid molecule, and selecting a compound that binds specifically to said nucleic acid molecule or polypeptide.

36. A kit useful for diagnosing disease comprising a first container containing a nucleic acid probe that hybridises under stringent conditions with a nucleic acid molecule according to any one of claims 7-9; a second container containing 10 primers useful for amplifying said nucleic acid molecule; and instructions for using the probe and primers for facilitating the diagnosis of disease.

37. The kit of claim 36, further comprising a third container holding an agent for digesting unhybridised RNA.

38. A kit comprising an array of nucleic acid molecules, at least one of which is a 15 nucleic acid molecule according to any one of claims 7-9.

39. A kit comprising one or more antibodies that bind to a polypeptide as recited in any one of claims 1-6; and a reagent useful for the detection of a binding reaction between said antibody and said polypeptide.

40. A transgenic or knockout non-human animal that has been transformed to express 20 higher, lower or absent levels of a polypeptide according to any one of claims 1-6.

41. A method for screening for a compound effective to treat disease, by contacting a non-human transgenic animal according to claim 40 with a candidate compound and determining the effect of the compound on the disease of the animal.

42. A method according to claims 31-37 or claim 41, wherein said disease is one of 25 the diseases set forth in claim 30.